ClinicalTrials.gg
CompletedNCT01309737Updated Sep 19, 2014Results posted

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of CP-690,550 and CP-690,550 in Psoriasis, sponsored by Pfizer. Completed at 94 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
3rd of 19
960 · median 135
Started
2011
with 2 others
Phase 3
9 of 19
1 open now
Registered
8th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 9 in phase 3, and was the 8th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.

03

Conditions studied

  • Psoriasis

Keywords

  • Xeljanz
  • tofacitinib
  • Jak-inhibitor
  • oral treatment
  • chronic
  • severe
  • moderate
  • Pruritus
  • Itch
  • DLQI
  • treatment
  • safety
  • efficacy
  • CP-690,550
  • Plaque Psoriasis
  • Psoriasis Vulgaris
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering at least 10% of body surface area
  • A Psoriasis Area and Severity Index (PASI) score of 12 or greater
  • Are considered to be candidates for systemic or light therapy
  • Have no evidence of active or latent tuberculosis

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug-induced forms of psoriasis
  • Cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)
  • Any uncontrolled significant medical condition
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
960 participants (actual)

Study arms

  • Experimental
    Active Treatment 10 mg BID

    Drug: CP-690,550

  • Experimental
    Active Treatment 5 mg BID

    Drug: CP-690,550

  • Placebo comparator
    Placebo Treatment

    Drug: Placebo/CP-690,550

Interventions

  • 10 mg oral BID, Continuous treatment for 52 Weeks

  • 5 mg oral BID, Continuous treatment for 52 Weeks

  • DrugPlacebo/CP-690,550

    0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)

  • DrugPlacebo/CP-690,550

    0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 16

  2. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline, Week 16

  2. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.

    Time frame: Week 16

  3. Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline

  4. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16

    The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline, Week 4,16

  5. Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 4

  6. Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

    Time frame: Week 4

  7. Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.

    Time frame: Baseline, Week 16

  8. Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).

    Time frame: Week 52

  9. Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52

    The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).

    Time frame: Week 52

  10. Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52

    The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).

    Time frame: Week 52

  11. Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Baseline up to Week 16

  12. Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Baseline up to Week 16

  13. Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Baseline up to Week 16

  14. Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  15. Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  16. Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  17. Psoriasis Area and Severity Index (PASI) Score

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52

  18. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52

  19. Psoriasis Area and Severity Index (PASI) Component Scores

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 and where higher scores indicate greater severity of psoriatic lesions.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  20. Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 where higher scores indicate greater severity of psoriatic lesions.

    Time frame: Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52

  21. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline, Week 2, 4, 8, 12,16, 20, 28, 40, 52

  22. Total Body Surface Area (BSA) With Psoriasis

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline, Week 2, 4, 8,16, 20, 28, 40, 52

  23. Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  24. Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least a 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported.

    Time frame: Week 2, 4, 8,12,16, 20, 28, 40, 52

  25. Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response is reported.

    Time frame: Week 2, 4, 8,12,16, 20, 28, 40, 52

  26. Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked).

    Time frame: Week 2, 4, 8,12,16, 20, 28, 40, 52

  27. Nail Psoriasis Severity Index (NAPSI) Score

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.'n' signifies participants evaluable at specified time point for each arm.

    Time frame: Baseline, Week 8, 16, 20, 28, 40, 52

  28. Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'n' signifies participants evaluable at specified time point for each arm.

    Time frame: Baseline,Week 8, 16, 20, 28, 40, 52

  29. Number of Affected Nails

    Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number of psoriasis affected nails (presence of psoriatic manifestations on the nail matrix / nail bed) were assessed and reported. 'N' (number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.

    Time frame: Baseline, Week 8, 16, 20, 28, 40, 52

  30. Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'N' (number of participants analyzed) signifies participants with baseline nail psoriasis and who were unique in longitudinal model.

    Time frame: Baseline,Week 8,16, 20, 28, 40, 52

  31. Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.

    Time frame: Week 8, 16, 20, 28, 40, 52

  32. Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.

    Time frame: Week 8,16, 20, 28, 40, 52

  33. Itch Severity Item (ISI) Score

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

    Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52

  34. Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28 , 40, 52

  35. Dermatology Life Quality Index (DLQI) Score

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52

  36. Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. Here 'N' (number of participants analyzed) signifies the unique participants in the longitudinal model.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  37. 36-Item Short-Form Health Survey Version 2, Acute (SF-36)

    36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

    Time frame: Baseline, Week 16, 28, 52

  38. Hospital Anxiety and Depression Scale (HADS) Score

    HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale and 7 items comprising the depression subscale. Each item has response options ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total HADS score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 8, 16, 28, 52

  39. Work Limitation Questionnaire (WLQ) Index Score

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands Scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).

    Time frame: Baseline, Week 8, 16, 28, 52

  40. Percentage of Participants With Patient Global Assessment (PtGA) Scale Response

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).

    Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52

  41. Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response

    The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study treatment.

    Time frame: Week 16, 28, 52

  42. Joint Pain Assessment (JPA) Score

    The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain".

    Time frame: Baseline, Week 8,16, 28, 52

  43. Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline, Week 16, 28, 40, 52

  44. Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline,Week 16, 28, 40, 52

  45. Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist and Rheumatologist. Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

    Time frame: Baseline, Week 16

  46. Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants (currently employed \[Emp\]) answered (Yes/No \[Y/N\]): "Were you absent or on sick leave from work due to psoriasis today?", and participants (unemployed \[UEmp\]) answered (Yes/No): "Are you unemployed due to your psoriasis?" Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.

    Time frame: Baseline, Week 16

  47. Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.

    Time frame: Week 16

  48. Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

    Time frame: Baseline, Week 16

  49. Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

    Time frame: Baseline, Week 16

  50. Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work

    The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means "ability to work was not affected by psoriasis", and 10 means "ability to work was completely affected by psoriasis". Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.

    Time frame: Baseline, Week 16

  51. Family Dermatology Life Quality Index (FDLQI) Score

    The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

    Time frame: Baseline, Week 16, 52

07

Results

Posted Sep 19, 2014

Participant flow

Week 0 to 16
Participant flow — Week 0 to 16
MilestoneCP-690,550 5mgCP-690,550 10 mgPlaceboPlacebo, CP-690,550 5 mgPlacebo,CP-690,550 10 mg
Started38338119600
Treated38238119600
Completed33134115200
Not completed52404400
Withdrew: Death10100
Withdrew: Adverse event1110500
Withdrew: Lack of efficacy1522400
Withdrew: Lost to follow-up78300
Withdrew: Withdrawal by subject76700
Withdrew: Other1014400
Withdrew: Randomized, but not treated10000
Week 16 to 52
Participant flow — Week 16 to 52
MilestoneCP-690,550 5mgCP-690,550 10 mgPlaceboPlacebo, CP-690,550 5 mgPlacebo,CP-690,550 10 mg
Started33134107577
Completed19823804144
Not completed13310303433
Withdrew: Death00001
Withdrew: Adverse event77065
Withdrew: Lack of efficacy1077602521
Withdrew: Lost to follow-up42014
Withdrew: Withdrawal by subject56002
Withdrew: Other1012020

Outcome measures

PrimaryPercentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 1646.0159.0910.88
Statistical analysis
  • CP-690,550 5mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).) · Odds ratio (or): 10.20 · 95% CI 5.33 to 17.68
  • CP-690,550 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).) · Odds ratio (or): 20.43 · 95% CI 8.99 to 30.59
  • CP-690,550 5mg vs CP-690,550 10 mg · Normal approximation · p = 0.0003 · Percent difference: 13.08 · 95% CI 5.99 to 20.17
SecondaryPercent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16
percent changeCP-690,550 5mgCP-690,550 10 mgPlacebo
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16-54.86 ± 2.12-67.22 ± 2.11-9.12 ± 3.02
Statistical analysis
  • CP-690,550 5mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Least squares (ls) mean difference: -45.73 · 95% CI -52.98 to -38.49
  • CP-690,550 10 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -58.10 · 95% CI -65.33 to -50.86
  • CP-690,550 5mg vs CP-690,550 10 mg · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -12.36 · 95% CI -18.24 to -6.48
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 1624.4738.775.18
Statistical analysis
  • CP-690,550 5mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 8.50 · 95% CI 3.48 to 17.31
  • CP-690,550 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 24.53 · 95% CI 8.08 to 46.22
  • CP-690,550 5mg vs CP-690,550 10 mg · Normal Approximation · p = <0.0001 · Percent difference: 14.30 · 95% CI 7.72 to 20.88
SecondaryDermatology Life Quality Index (DLQI) Total Score

The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Dermatology Life Quality Index (DLQI) Total Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo
Dermatology Life Quality Index (DLQI) Total Score13.22 ± 7.2112.69 ± 7.1813.19 ± 7.35
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16

The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline, Week 4,16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo
Change at Week 4-5.55 ± 0.24-6.88 ± 0.25-2.57 ± 0.35
Change at Week 16-7.28 ± 0.30-8.92 ± 0.31-2.82 ± 0.44
Statistical analysis
  • CP-690,550 5mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -2.97 · 95% CI -3.80 to -2.14
  • CP-690,550 10 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -4.30 · 95% CI -5.13 to -3.47
  • CP-690,550 5mg vs CP-690,550 10 mg · Mixed Models Analysis · p = 0.0001 · Ls mean difference: -1.33 · 95% CI -2.01 to -0.65
  • CP-690,550 5mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -4.46 · 95% CI -5.51 to -3.42
  • CP-690,550 10 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -6.10 · 95% CI -7.14 to -5.05
  • CP-690,550 5mg vs CP-690,550 10 mg · Mixed Models Analysis · p = 0.0002 · Ls mean difference: -1.63 · 95% CI -2.48 to -0.79
SecondaryPercentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 417.0227.815.18
Statistical analysis
  • CP-690,550 5mg vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 3.63 · 95% CI 1.89 to 8.95
  • CP-690,550 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 8.25 · 95% CI 4.08 to 19.95
  • CP-690,550 5mg vs CP-690,550 10 mg · Normal Approximation · p = 0.0004 · Percent difference: 10.79 · 95% CI 4.87 to 16.71
SecondaryPercentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 47.4514.174.15
Statistical analysis
  • CP-690,550 5mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1786 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 1.72 · 95% CI 0.74 to 4.62
  • CP-690,550 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0003 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 4.18 · 95% CI 1.77 to 10.25
  • CP-690,550 5mg vs CP-690,550 10 mg · Normal Approximation · p = 0.0029 · Percent difference: 6.72 · 95% CI 2.30 to 11.14
PrimaryPercentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 1646.0159.6311.40
Statistical analysis
  • CP-690,550 5mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).) · Odds ratio (or): 9.06 · 95% CI 5.02 to 16.45
  • CP-690,550 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).) · Odds ratio (or): 17.97 · 95% CI 9.00 to 30.73
  • CP-690,550 5mg vs CP-690,550 10 mg · Normal Approximation · p = 0.0002 · Percent difference: 13.62 · 95% CI 6.54 to 20.69
SecondaryPercent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16
percent changeCP-690,550 5mgCP-690,550 10 mgPlacebo
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16-21.62 ± 7.65-25.97 ± 7.8715.82 ± 11.27
Statistical analysis
  • CP-690,550 5mg vs Placebo · Mixed Models Analysis · p = 0.0062 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -37.44 · 95% CI -64.19 to -10.68
  • CP-690,550 10 mg vs Placebo · Mixed Models Analysis · p = 0.0025 (Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Ls mean difference: -41.79 · 95% CI -68.80 to -14.78
  • CP-690,550 5mg vs CP-690,550 10 mg · Mixed Models Analysis · p = 0.6920 · Ls mean difference: -4.35 · 95% CI -25.91 to 17.21
SecondaryPercent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).

Time frame:
Week 52
Reported as:
Number · percent probability of response
Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52
percent probability of responseCP-690,550 5mgCP-690,550 10 mg
Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 5263.55 (55.67 to 70.40)71.71 (65.12 to 77.28)
SecondaryPercent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52

The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).

Time frame:
Week 52
Reported as:
Number · percent probability of response
Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52
percent probability of responseCP-690,550 5mgCP-690,550 10 mg
Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 5274.38 (66.94 to 80.39)78.99 (72.80 to 83.92)
SecondaryPercent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52

The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).

Time frame:
Week 52
Reported as:
Number · percent probability of response
Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52
percent probability of responseCP-690,550 5mgCP-690,550 10 mg
Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 5270.33 (59.79 to 78.60)63.83 (55.21 to 71.23)
SecondaryTime to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Baseline up to Week 16
Reported as:
Median · weeks
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
weeksCP-690,550 5mgCP-690,550 10 mgPlacebo
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'12.0 (12.0 to 16.0)8.0 (8.0 to 12.0)NA (NA to NA)
Statistical analysis
  • CP-690,550 5mg vs Placebo · Log Rank · p = <0.0001
  • CP-690,550 10 mg vs Placebo · Log Rank · p = <0.0001
  • CP-690,550 5mg vs CP-690,550 10 mg · Log Rank · p = <0.0001
SecondaryTime to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Baseline up to Week 16
Reported as:
Median · weeks
Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response
weeksCP-690,550 5mgCP-690,550 10 mgPlacebo
Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response16.0 (16.0 to NA)12.0 (NA to NA)NA (NA to NA)
Statistical analysis
  • CP-690,550 5mg vs Placebo · Log Rank · p = <0.0001
  • CP-690,550 10 mg vs Placebo · Log Rank · p = <0.0001
  • CP-690,550 5mg vs CP-690,550 10 mg · Log Rank · p = <0.0001
SecondaryTime to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Baseline up to Week 16
Reported as:
Median · weeks
Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response
weeksCP-690,550 5mgCP-690,550 10 mgPlacebo
Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response8.0 (8.0 to 12.0)8.0 (NA to NA)NA (NA to NA)
Statistical analysis
  • CP-690,550 5mg vs Placebo · Log Rank · p = <0.0001
  • CP-690,550 10 mg vs Placebo · Log Rank · p = <0.0001
  • CP-690,550 5mg vs CP-690,550 10 mg · Log Rank · p = <0.0001
SecondaryPercentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, Then CP-690,550 5 mgPlacebo, Then CP-690,550 10 mg
Week 25.32 (3.05 to 7.59)9.63 (6.64 to 12.61)2.70 (0.00 to 6.40)3.95 (0.00 to 8.33)
Week 417.02 (13.22 to 20.82)27.81 (23.27 to 32.35)6.76 (1.04 to 12.48)5.26 (0.24 to 10.28)
Week 833.51 (28.74 to 38.28)49.20 (44.13 to 54.26)12.16 (4.72 to 19.61)7.89 (1.83 to 13.96)
Week 1241.49 (36.51 to 46.47)55.35 (50.31 to 60.39)14.86 (6.76 to 22.97)7.89 (1.83 to 13.96)
Week 1646.01 (40.97 to 51.05)59.09 (54.11 to 64.07)17.57 (8.90 to 26.24)9.21 (2.71 to 15.71)
Week 2047.34 (42.29 to 52.39)59.09 (54.11 to 64.07)33.78 (23.01 to 44.56)40.79 (29.74 to 51.84)
Week 2850.53 (45.48 to 55.59)62.03 (57.11 to 66.95)52.70 (41.33 to 64.08)68.42 (57.97 to 78.87)
Week 4042.55 (37.56 to 47.55)55.88 (50.85 to 60.91)43.24 (31.96 to 54.53)59.21 (48.16 to 70.26)
Week 5236.97 (32.09 to 41.85)50.00 (44.93 to 55.07)36.49 (25.52 to 47.45)40.79 (29.74 to 51.84)
SecondaryPercentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline: Clear(n=376,374,74,76)0 (3.05 to 7.59)0 (6.64 to 12.61)0 (0.00 to 6.40)0 (0.00 to 8.33)
Baseline: Almost clear(n=376,374,74,76)0 (13.22 to 20.82)0 (23.27 to 32.35)0 (1.04 to 12.48)0 (0.24 to 10.28)
Baseline: Mild(n=376,374,74,76)0 (28.74 to 38.28)0 (44.13 to 54.26)0 (4.72 to 19.61)0 (1.83 to 13.96)
Baseline: Moderate(n=376,374,74,76)82.4 (36.51 to 46.47)81.6 (50.31 to 60.39)87.8 (6.76 to 22.97)84.2 (1.83 to 13.96)
Baseline: Severe(n=376,374,74,76)17.6 (40.97 to 51.05)18.4 (54.11 to 64.07)12.2 (8.90 to 26.24)15.8 (2.71 to 15.71)
Week 2: Clear(n=370,367,73,76)0.30.300
Week 2: Almost clear(n=370,367,73,76)5.19.52.73.9
Week 2: Mild(n=370,367,73,76)30.531.18.215.8
Week 2: Moderate(n=370,367,73,76)55.451.574.071.1
Week 2: Severe(n=370,367,73,76)8.67.615.19.2
Week 4: Clear(n=362,366,74,75)1.72.200
Week 4: Almost clear(n=362,366,74,75)16.026.26.85.3
Week 4: Mild(n=362,366,74,75)40.339.117.628.0
Week 4: Moderate(n=362,366,74,75)38.429.066.261.3
Week 4: Severe(n=362,366,74,75)3.63.69.55.3
Week 8: Clear(n=354,356,74,76)7.110.12.72.6
Week 8: Almost clear(n=354,356,74,76)28.541.69.55.3
Week 8: Mild(n=354,356,74,76)34.730.327.032.9
Week 8: Moderate(n=354,356,74,76)26.616.651.452.6
Week 8: Severe(n=354,356,74,76)3.11.49.56.6
Week 12: Clear(n=347,348,74,76)11.520.15.42.6
Week 12: Almost clear(n=347,348,74,76)33.439.49.55.3
Week 12: Mild(n=347,348,74,76)32.626.429.738.2
Week 12: Moderate(n=347,348,74,76)19.012.647.346.1
Week 12: Severe(n=347,348,74,76)3.51.48.17.9
Week 16: Clear(n=340,345,74,76)16.527.06.82.6
Week 16: Almost clear(n=340,345,74,76)34.437.110.86.6
Week 16: Mild(n=340,345,74,76)27.424.125.738.2
Week 16 : Moderate(n=340,345,74,76)19.19.650.047.4
Week 16: Severe(n=340,345,74,76)2.62.36.85.3
Week 20: Clear(n=327,338,74,76)19.330.210.85.3
Week 20: Almost clear(n=327,338,74,76)35.235.223.035.5
Week 20: Mild(n=327,338,74,76)29.424.041.940.8
Week 20: Moderate(n=327,338,74,76)15.39.824.318.4
Week 20: Severe(n=327,338,74,76)0.90.900
Week 28: Clear(n=305,328,69,72)22.630.820.330.6
Week 28: Almost clear(n=305,328,69,72)39.739.936.241.7
Week 28: Mild(n=305,328,69,72)25.919.223.218.1
Week 28: Moderate(n=305,328,69,72)10.87.920.39.7
Week 28: Severe(n=305,328,69,72)1.02.100
Week 40: Clear(n=213,263,46,55)34.335.432.638.2
Week 40: Almost clear(n=213,263,46,55)40.844.137.043.6
Week 40: Mild(n=213,263,46,55)18.813.721.716.4
Week 40: Moderate(n=213,263,46,55)5.25.76.51.8
Week 40: Severe(n=213,263,46,55)0.91.12.20
Week 52: Clear(n=194,239,38,42)36.139.334.240.5
Week 52: Almost clear(n=194,239,38,42)35.638.936.833.3
Week 52: Mild(n=194,239,38,42)22.715.921.121.4
Week 52: Moderate(n=194,239,38,42)5.75.47.94.8
Week 52: Severe(n=194,239,38,42)00.400
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo,CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 21.33 (0.17 to 2.49)1.87 (0.50 to 3.25)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 47.45 (4.79 to 10.10)14.17 (10.64 to 17.71)5.41 (0.25 to 10.56)3.95 (0.00 to 8.33)
Week 824.47 (20.12 to 28.81)39.30 (34.35 to 44.25)8.11 (1.89 to 14.33)5.26 (0.24 to 10.28)
Week 1238.56 (33.64 to 43.48)53.48 (48.42 to 58.53)13.51 (5.72 to 21.30)6.58 (1.01 to 12.15)
Week 1646.01 (40.97 to 51.05)59.63 (54.65 to 64.60)16.22 (7.82 to 24.61)11.84 (4.58 to 19.11)
Week 2049.47 (44.41 to 54.52)62.03 (57.11 to 66.95)32.43 (21.77 to 43.10)38.16 (27.24 to 49.08)
Week 2852.13 (47.08 to 57.18)66.31 (61.52 to 71.10)52.70 (41.33 to 64.08)64.47 (53.71 to 75.23)
Week 4046.01 (40.97 to 51.05)60.43 (55.47 to 65.38)50.00 (38.61 to 61.39)59.21 (48.16 to 70.26)
Week 5242.02 (37.03 to 47.01)52.41 (47.34 to 57.47)41.89 (30.65 to 53.13)44.74 (33.56 to 55.92)
SecondaryPsoriasis Area and Severity Index (PASI) Score

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, Then CP-690,550 10 mg
Baseline (n=376,374,74,76)22.96 ± 8.8021.88 ± 8.4122.58 ± 8.6222.36 ± 8.43
Week 2 (n=369,367,73,76)18.62 ± 8.4717.19 ± 8.9421.46 ± 8.8819.53 ± 7.72
Week 4 (n=363,366,74,76)14.84 ± 8.2712.60 ± 8.4419.43 ± 9.3518.87 ± 7.86
Week 8 (n=354,356,74,76)10.98 ± 8.398.23 ± 7.6517.42 ± 9.4218.16 ± 9.04
Week 12 (n=347,348,74,76)9.22 ± 8.586.39 ± 7.2217.07 ± 10.2717.29 ± 8.44
Week 16 (n=340,345,74,76)8.16 ± 8.775.36 ± 6.7116.59 ± 10.8316.59 ± 8.67
Week 20 (n=327,338,74,76)6.76 ± 7.714.46 ± 5.8310.62 ± 8.719.28 ± 8.20
Week 28 (n=305,327,69,72)5.62 ± 6.564.15 ± 6.136.71 ± 7.415.38 ± 8.35
Week 40 (n=213,263,46,55)3.33 ± 4.652.74 ± 4.664.21 ± 6.192.90 ± 3.92
Week 52 (n=194,239,38,42)3.24 ± 4.162.60 ± 3.893.49 ± 4.132.88 ± 3.56
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo,CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Change at Week 2-4.09 ± 0.28-4.94 ± 0.28-1.04 ± 0.62-2.87 ± 0.61
Change at Week 4-7.87 ± 0.34-9.47 ± 0.34-3.09 ± 0.76-3.65 ± 0.75
Change at Week 8-11.68 ± 0.40-13.70 ± 0.40-5.11 ± 0.89-4.23 ± 0.87
Change at Week 12-13.35 ± 0.42-15.56 ± 0.42-5.46 ± 0.92-5.10 ± 0.91
Change at Week 16-14.23 ± 0.44-16.44 ± 0.44-5.94 ± 0.96-5.80 ± 0.95
Change at Week 20-15.54 ± 0.41-17.36 ± 0.40-11.90 ± 0.88-13.12 ± 0.87
Change at Week 28-16.50 ± 0.41-17.65 ± 0.41-15.08 ± 0.89-17.14 ± 0.89
Change at Week 40-15.84 ± 0.46-16.98 ± 0.45-14.33 ± 0.98-16.42 ± 0.96
Change at Week 52-15.40 ± 0.47-16.42 ± 0.45-13.92 ± 1.02-16.16 ± 0.99
SecondaryPsoriasis Area and Severity Index (PASI) Component Scores

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 and where higher scores indicate greater severity of psoriatic lesions.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Component Scores
units on a scaleCP-690,550 10 mgCP-690,550 5mgPlacebo, CP-690,550 5 mgPlacebo, Then CP-690,550 10 mg
Baseline:Erythema(Head\Neck)(n=376,374,74,76)2.30 ± 1.042.35 ± 0.972.36 ± 0.922.29 ± 0.86
Baseline:Erythema(Upper limbs)(n=376,374,74,76)2.90 ± 0.612.89 ± 0.662.82 ± 0.652.86 ± 0.71
Baseline:Erythema(Trunk)(n=376,374,74,76)2.93 ± 0.702.92 ± 0.702.96 ± 0.712.80 ± 0.80
Baseline:Erythema(Lower limbs)(n=376,374,74,76)3.18 ± 0.603.18 ± 0.633.16 ± 0.503.17 ± 0.64
Baseline:Induration(Head\Neck)(n=376,374,74,76)2.02 ± 1.032.11 ± 1.052.24 ± 0.902.00 ± 0.95
Baseline:Induration(Upper limbs)(n=376,374,74,76)2.74 ± 0.702.79 ± 0.692.66 ± 0.632.86 ± 0.74
Baseline:Induration(Trunk)(n=376,374,74,76)2.72 ± 0.772.69 ± 0.762.69 ± 0.682.64 ± 0.96
Baseline:Induration(Lower limbs)(n=376,374,74,76)2.99 ± 0.702.95 ± 0.692.86 ± 0.632.92 ± 0.74
Baseline:Scaling(Head\Neck)(n=376,374,74,76)2.32 ± 1.102.33 ± 1.092.47 ± 1.052.30 ± 1.03
Baseline:Scaling(Upper limbs)(n=376,374,74,76)2.77 ± 0.732.77 ± 0.732.78 ± 0.732.79 ± 0.81
Baseline:Scaling(Trunk)(n=376,374,74,76)2.68 ± 0.772.69 ± 0.772.77 ± 0.792.61 ± 0.95
Baseline:Scaling(Lower limbs)(n=376,374,74,76)3.04 ± 0.663.02 ± 0.743.03 ± 0.623.03 ± 0.80
Week 2:Erythema(Head\Neck)(n=369,367,73,76)1.76 ± 1.071.86 ± 1.052.30 ± 0.892.07 ± 0.93
Week 2:Erythema(Upper limbs)(n=369,367,73,76)2.27 ± 0.822.41 ± 0.822.70 ± 0.742.57 ± 0.87
Week 2:Erythema(Trunk)(n=369,367,73,76)2.35 ± 0.892.45 ± 0.852.82 ± 0.732.55 ± 0.90
Week 2:Erythema(Lower limbs)(n=369,367,73,76)2.63 ± 0.832.78 ± 0.813.07 ± 0.512.91 ± 0.85
Week 2:Induration(Head\Neck)(n=369,367,73,76)1.53 ± 1.071.73 ± 1.102.11 ± 0.861.86 ± 0.96
Week 2:Induration(Upper limbs)(n=369,367,73,76)2.20 ± 0.852.36 ± 0.822.53 ± 0.712.53 ± 0.84
Week 2:Induration(Trunk)(n=369,367,73,76)2.22 ± 0.912.33 ± 0.872.52 ± 0.712.38 ± 0.92
Week 2:Induration(Lower limbs)(n=369,367,73,76)2.48 ± 0.832.60 ± 0.812.73 ± 0.712.66 ± 0.79
Week 2:Scaling(Head\Neck)(n=369,367,73,76)1.69 ± 1.151.80 ± 1.192.33 ± 1.042.11 ± 1.03
Week 2:Scaling(Upper limbs)(n=369,367,73,76)2.16 ± 0.922.25 ± 0.922.56 ± 0.902.36 ± 0.80
Week 2:Scaling(Trunk)(n=369,367,73,76)2.12 ± 0.952.18 ± 0.922.44 ± 0.962.29 ± 0.86
Week 2:Scaling(Lower limbs)(n=369,367,73,76)2.48 ± 0.902.53 ± 0.912.71 ± 0.842.67 ± 0.81
Week 4:Erythema(Head\Neck)(n=363,366,74,75)1.31 ± 1.091.49 ± 1.042.11 ± 0.902.05 ± 0.97
Week 4:Erythema(Upper limbs)(n=363,366,74,75)1.82 ± 0.892.00 ± 0.862.53 ± 0.812.53 ± 0.89
Week 4:Erythema(Trunk)(n=363,366,74,75)1.89 ± 0.952.07 ± 0.932.50 ± 0.952.49 ± 0.92
Week 4:Erythema(Lower limbs)(n=363,366,74,75)2.11 ± 0.902.34 ± 0.902.74 ± 0.762.80 ± 0.93
Week 4:Induration(Head\Neck)(n=363,366,74,75)1.08 ± 1.001.30 ± 1.051.86 ± 0.911.72 ± 0.99
Week 4:Induration(Upper limbs)(n=363,366,74,75)1.67 ± 0.911.91 ± 0.862.41 ± 0.772.40 ± 0.89
Week 4:Induration(Trunk)(n=363,366,74,75)1.72 ± 0.991.89 ± 0.942.27 ± 0.912.36 ± 0.90
Week 4:Induration(Lower limbs)(n=363,366,74,75)1.93 ± 0.952.16 ± 0.932.55 ± 0.802.51 ± 0.84
Week 4:Scaling(Head\Neck)(n=363,366,74,75)1.20 ± 1.111.42 ± 1.162.00 ± 1.071.95 ± 1.09
Week 4:Scaling(Upper limbs)(n=363,366,74,75)1.64 ± 0.971.85 ± 0.922.31 ± 0.942.25 ± 0.89
Week 4:Scaling(Trunk)(n=363,366,74,75)1.61 ± 1.001.83 ± 0.972.23 ± 1.082.17 ± 0.79
Week 4:Scaling(Lower limbs)(n=363,366,74,75)1.95 ± 1.002.13 ± 1.002.57 ± 0.882.45 ± 0.90
Week 8:Erythema(Head\Neck)(n=354,356,74,76)0.96 ± 1.021.24 ± 1.041.85 ± 1.021.79 ± 1.04
Week 8:Erythema(Upper limbs)(n=354,356,74,76)1.40 ± 0.911.70 ± 0.922.28 ± 0.822.47 ± 0.93
Week 8:Erythema(Trunk)(n=354,356,74,76)1.37 ± 1.021.75 ± 1.052.27 ± 0.962.46 ± 0.97
Week 8:Erythema(Lower limbs)(n=354,356,74,76)1.60 ± 0.991.92 ± 1.042.55 ± 0.882.72 ± 0.83
Week 8:Induration(Head\Neck)(n=354,356,74,76)0.78 ± 0.941.05 ± 1.041.62 ± 1.001.64 ± 1.07
Week 8:Induration(Upper limbs)(n=354,356,74,76)1.29 ± 0.961.59 ± 0.972.14 ± 0.852.33 ± 0.87
Week 8:Induration(Trunk)(n=354,356,74,76)1.21 ± 1.031.54 ± 1.052.09 ± 0.972.26 ± 0.91
Week 8:Induration(Lower limbs)(n=354,356,74,76)1.40 ± 1.001.71 ± 1.032.42 ± 0.922.51 ± 0.82
Week 8:Scaling(Head\Neck)(n=354,356,74,76)0.89 ± 1.051.13 ± 1.101.82 ± 1.061.79 ± 1.10
Week 8:Scaling(Upper limbs)(n=354,356,74,76)1.29 ± 1.011.53 ± 1.002.18 ± 0.932.20 ± 0.91
Week 8:Scaling(Trunk)(n=354,356,74,76)1.11 ± 1.051.42 ± 1.072.03 ± 1.062.14 ± 0.96
Week 8:Scaling(Lower limbs)(n=354,356,74,76)1.36 ± 1.081.68 ± 1.112.34 ± 0.982.41 ± 0.88
Week 12:Erythema(Head\Neck)(n=347,348,74,76)0.78 ± 0.961.10 ± 1.051.86 ± 1.091.93 ± 1.04
Week 12:Erythema(Upper limbs)(n=347,348,74,76)1.19 ± 0.921.49 ± 0.972.18 ± 0.882.29 ± 0.98
Week 12:Erythema(Trunk)(n=347,348,74,76)1.11 ± 1.031.52 ± 1.132.24 ± 1.002.38 ± 0.94
Week 12:Erythema(Lower limbs)(n=347,348,74,76)1.32 ± 1.051.72 ± 1.092.50 ± 0.932.61 ± 1.05
Week 12:Induration(Head\Neck)(n=347,348,74,76)0.63 ± 0.900.93 ± 1.051.61 ± 1.041.66 ± 1.01
Week 12:Induration(Upper limbs)(n=347,348,74,76)1.13 ± 0.991.37 ± 1.022.09 ± 0.942.21 ± 0.91
Week 12:Induration(Trunk)(n=347,348,74,76)0.96 ± 1.021.30 ± 1.112.11 ± 1.082.21 ± 0.93
Week 12:Induration(Lower limbs)(n=347,348,74,76)1.12 ± 1.041.50 ± 1.112.36 ± 0.972.42 ± 0.91
Week 12:Scaling(Head\Neck)(n=347,348,74,76)0.74 ± 1.010.99 ± 1.101.77 ± 1.101.78 ± 1.08
Week 12:Scaling(Upper limbs)(n=347,348,74,76)1.11 ± 1.011.38 ± 1.092.04 ± 1.012.09 ± 0.87
Week 12:Scaling(Trunk)(n=347,348,74,76)0.88 ± 1.011.22 ± 1.121.97 ± 1.152.11 ± 1.01
Week 12:Scaling(Lower limbs)(n=347,348,74,76)1.07 ± 1.051.50 ± 1.162.30 ± 1.032.30 ± 0.99
Week 16:Erythema(Head\Neck)(n=340,345,74,76)0.74 ± 0.951.06 ± 1.081.91 ± 1.121.75 ± 1.05
Week 16:Erythema(Upper limbs)(n=340,345,74,76)1.08 ± 0.971.37 ± 1.042.09 ± 1.022.28 ± 0.89
Week 16:Erythema(Trunk)(n=340,345,74,76)0.94 ± 1.061.34 ± 1.162.08 ± 1.112.30 ± 1.03
Week 16:Erythema(Lower limbs)(n=340,345,74,76)1.17 ± 1.071.51 ± 1.132.42 ± 1.052.46 ± 1.04
Week 16:Induration(Head\Neck)(n=340,345,74,76)0.58 ± 0.860.89 ± 1.041.66 ± 1.061.53 ± 1.00
Week 16:Induration(Upper limbs)(n=340,345,74,76)1.05 ± 1.021.28 ± 1.112.07 ± 1.092.16 ± 0.90
Week 16:Induration(Trunk)(n=340,345,74,76)0.79 ± 1.021.16 ± 1.152.01 ± 1.192.11 ± 1.01
Week 16:Induration(Lower limbs)(n=340,345,74,76)1.01 ± 1.061.34 ± 1.142.31 ± 1.032.33 ± 0.89
Week 16:Scaling(Head\Neck)(n=340,345,74,76)0.68 ± 0.991.00 ± 1.151.74 ± 1.151.68 ± 1.16
Week 16:Scaling(Upper limbs)(n=340,345,74,76)1.03 ± 1.061.31 ± 1.172.04 ± 1.152.11 ± 0.86
Week 16:Scaling(Trunk)(n=340,345,74,76)0.75 ± 1.001.08 ± 1.151.84 ± 1.191.95 ± 1.08
Week 16:Scaling(Lower limbs)(n=340,345,74,76)1.00 ± 1.071.38 ± 1.172.16 ± 1.122.34 ± 1.04
Week 20:Erythema(Head\Neck)(n=327,338,74,76)0.68 ± 0.910.93 ± 1.001.34 ± 1.061.11 ± 1.04
Week 20:Erythema(Upper limbs)(n=327,338,74,76)0.98 ± 0.921.23 ± 1.011.59 ± 0.961.55 ± 0.91
Week 20:Erythema(Trunk)(n=327,338,74,76)0.81 ± 0.991.14 ± 1.111.59 ± 1.121.59 ± 0.98
Week 20:Erythema(Lower limbs)(n=327,338,74,76)1.02 ± 1.051.34 ± 1.051.82 ± 1.161.78 ± 0.96
Week 20:Induration(Head\Neck)(n=327,338,74,76)0.48 ± 0.760.77 ± 0.931.11 ± 0.920.89 ± 0.93
Week 20:Induration(Upper limbs)(n=327,338,74,76)0.96 ± 1.001.14 ± 1.061.43 ± 0.921.37 ± 0.86
Week 20:Induration(Trunk)(n=327,338,74,76)0.71 ± 0.960.98 ± 1.081.41 ± 1.061.26 ± 0.88
Week 20:Induration(Lower limbs)(n=327,338,74,76)0.87 ± 1.001.20 ± 1.061.68 ± 0.991.46 ± 0.94
Week 20:Scaling(Head\Neck)(n=327,338,74,76)0.63 ± 0.960.84 ± 1.011.11 ± 0.991.03 ± 1.06
Week 20:Scaling(Upper limbs)(n=327,338,74,76)1.00 ± 1.051.14 ± 1.071.41 ± 1.051.37 ± 0.89
Week 20:Scaling(Trunk)(n=327,338,74,76)0.66 ± 0.930.89 ± 1.061.31 ± 1.081.21 ± 1.02
Week 20:Scaling(Lower limbs)(n=327,338,74,76)0.89 ± 1.081.17 ± 1.101.43 ± 0.991.50 ± 1.09
Week 28:Erythema(Head\Neck)(n=305,327,69,72)0.65 ± 0.930.88 ± 0.950.90 ± 1.060.76 ± 0.96
Week 28:Erythema(Upper limbs)(n=305,327,69,72)0.96 ± 0.981.17 ± 0.971.26 ± 1.011.15 ± 0.96
Week 28:Erythema(Trunk)(n=305,327,69,72)0.81 ± 1.061.00 ± 1.071.09 ± 1.200.88 ± 1.05
Week 28:Erythema(Lower limbs)(n=305,327,69,72)0.96 ± 1.111.20 ± 1.021.39 ± 1.050.99 ± 1.04
Week 28:Induration(Head\Neck)(n=305,327,69,72)0.47 ± 0.750.71 ± 0.900.78 ± 0.970.60 ± 0.88
Week 28:Induration(Upper limbs)(n=305,327,69,72)0.95 ± 1.021.10 ± 1.051.10 ± 0.930.94 ± 0.99
Week 28:Induration(Trunk)(n=305,327,69,72)0.67 ± 0.940.90 ± 1.040.94 ± 1.080.76 ± 1.01
Week 28:Induration(Lower limbs)(n=305,327,69,72)0.80 ± 1.041.08 ± 1.041.29 ± 1.030.89 ± 1.08
Week 28:Scaling(Head\Neck)(n=305,327,69,72)0.60 ± 0.920.81 ± 0.970.80 ± 1.020.68 ± 0.96
Week 28:Scaling(Upper limbs)(n=305,327,69,72)0.96 ± 1.081.07 ± 1.071.20 ± 1.041.10 ± 1.02
Week 28:Scaling(Trunk)(n=305,327,69,72)0.63 ± 0.960.81 ± 1.000.96 ± 1.170.79 ± 1.01
Week 28:Scaling(Lower limbs)(n=305,327,69,72)0.84 ± 1.111.05 ± 1.071.22 ± 1.040.90 ± 1.05
Week 40:Erythema(Head\Neck)(n=213,263,46,55)0.48 ± 0.750.67 ± 0.850.72 ± 1.070.51 ± 0.72
Week 40:Erythema(Upper limbs)(n=213,263,46,55)0.76 ± 0.850.85 ± 0.870.98 ± 1.000.78 ± 0.88
Week 40:Erythema(Trunk)(n=213,263,46,55)0.62 ± 0.950.65 ± 0.880.72 ± 0.980.45 ± 0.74
Week 40:Erythema(Lower limbs)(n=213,263,46,55)0.72 ± 0.940.82 ± 0.931.00 ± 1.030.69 ± 0.81
Week 40:Induration(Head\Neck)(n=213,263,46,55)0.36 ± 0.640.48 ± 0.760.54 ± 0.910.38 ± 0.73
Week 40:Induration(Upper limbs)(n=213,263,46,55)0.73 ± 0.920.78 ± 0.910.89 ± 1.040.85 ± 1.01
Week 40:Induration(Trunk)(n=213,263,46,55)0.51 ± 0.890.52 ± 0.820.57 ± 0.930.45 ± 0.77
Week 40:Induration(Lower limbs)(n=213,263,46,55)0.62 ± 0.910.70 ± 0.890.85 ± 0.990.62 ± 0.80
Week 40:Scaling(Head\Neck)(n=213,263,46,55)0.46 ± 0.810.67 ± 0.950.67 ± 1.010.58 ± 0.96
Week 40:Scaling(Upper limbs)(n=213,263,46,55)0.74 ± 0.960.84 ± 1.030.89 ± 1.060.89 ± 1.03
Week 40:Scaling(Trunk)(n=213,263,46,55)0.47 ± 0.840.56 ± 0.910.57 ± 0.980.47 ± 0.84
Week 40:Scaling(Lower limbs)(n=213,263,46,55)0.63 ± 0.960.74 ± 0.950.93 ± 1.120.71 ± 0.90
Week 52:Erythema(Head\Neck)(n=194,239,38,42)0.48 ± 0.770.70 ± 0.900.68 ± 0.960.48 ± 0.77
Week 52:Erythema(Upper limbs)(n=194,239,38,42)0.77 ± 0.880.91 ± 0.931.05 ± 0.930.88 ± 1.04
Week 52:Erythema(Trunk)(n=194,239,38,42)0.60 ± 0.910.74 ± 1.010.76 ± 0.880.48 ± 0.71
Week 52:Erythema(Lower limbs)(n=194,239,38,42)0.76 ± 0.970.87 ± 1.010.84 ± 1.030.79 ± 1.05
Week 52:Induration(Head\Neck)(n=194,239,38,42)0.33 ± 0.600.49 ± 0.760.53 ± 0.800.33 ± 0.65
Week 52:Induration(Upper limbs)(n=194,239,38,42)0.69 ± 0.870.79 ± 0.930.95 ± 0.930.76 ± 0.88
Week 52:Induration(Trunk)(n=194,239,38,42)0.46 ± 0.740.55 ± 0.850.61 ± 0.820.50 ± 0.77
Week 52:Induration(Lower limbs)(n=194,239,38,42)0.64 ± 0.890.69 ± 0.920.76 ± 0.970.69 ± 1.00
Week 52:Scaling(Head\Neck)(n=194,239,38,42)0.45 ± 0.780.63 ± 0.870.58 ± 0.830.43 ± 0.77
Week 52:Scaling(Upper limbs)(n=194,239,38,42)0.70 ± 0.920.84 ± 0.970.95 ± 0.930.81 ± 0.97
Week 52:Scaling(Trunk)(n=194,239,38,42)0.45 ± 0.750.58 ± 0.880.66 ± 0.940.45 ± 0.74
Week 52:Scaling(Lower limbs)(n=194,239,38,42)0.64 ± 0.920.72 ± 0.950.89 ± 1.130.74 ± 0.99
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 where higher scores indicate greater severity of psoriatic lesions.

Time frame:
Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 2:Erythema(Head\Neck)(n=369,367,73,76)-0.48 ± 0.76-0.56 ± 0.77-0.05 ± 0.50-0.22 ± 0.53
Week 4:Erythema(Head\Neck)(n=363,366,74,75)-0.85 ± 0.97-1.01 ± 1.04-0.26 ± 0.70-0.25 ± 0.70
Week 8:Erythema(Head\Neck)(n=354,356,74,76)-1.09 ± 1.07-1.35 ± 1.12-0.51 ± 0.95-0.50 ± 0.82
Week 12:Erythema(Head\Neck)(n=347,348,74,76)-1.25 ± 1.17-1.54 ± 1.16-0.50 ± 1.01-0.36 ± 0.89
Week 16:Erythema(Head\Neck)(n=340,345,74,76)-1.27 ± 1.17-1.57 ± 1.17-0.46 ± 1.15-0.54 ± 0.90
Week 20:Erythema(Head\Neck)(n=327,338,74,76)-1.39 ± 1.16-1.62 ± 1.17-1.03 ± 1.06-1.18 ± 1.14
Week 28:Erythema(Head\Neck)(n=305,327,69,72)-1.46 ± 1.10-1.64 ± 1.18-1.42 ± 1.14-1.56 ± 1.10
Week 40:Erythema(Head\Neck)(n=213,263,46,55)-1.69 ± 1.05-1.79 ± 1.14-1.67 ± 1.21-1.78 ± 0.96
Week 52:Erythema(Head\Neck)(n=194,239,38,42)-1.64 ± 1.06-1.82 ± 1.11-1.66 ± 1.19-1.95 ± 1.06
Week 2:Erythema(Upper limbs)(n=369,367,73,76)-0.48 ± 0.71-0.63 ± 0.68-0.12 ± 0.47-0.29 ± 0.63
Week 4:Erythema(Upper limbs)(n=363,366,74,75)-0.89 ± 0.86-1.08 ± 0.90-0.30 ± 0.70-0.32 ± 0.70
Week 8:Erythema(Upper limbs)(n=354,356,74,76)-1.18 ± 0.98-1.51 ± 1.01-0.54 ± 0.88-0.38 ± 0.80
Week 12:Erythema(Upper limbs)(n=347,348,74,76)-1.40 ± 1.08-1.71 ± 1.05-0.65 ± 1.05-0.57 ± 0.88
Week 16:Erythema(Upper limbs)(n=340,345,74,76)-1.53 ± 1.16-1.81 ± 1.13-0.73 ± 1.19-0.58 ± 0.93
Week 20:Erythema(Upper limbs)(n=327,338,74,76)-1.66 ± 1.17-1.91 ± 1.11-1.23 ± 1.15-1.30 ± 1.06
Week 28:Erythema(Upper limbs)(n=305,327,69,72)-1.72 ± 1.13-1.92 ± 1.16-1.57 ± 1.23-1.72 ± 1.22
Week 40:Erythema(Upper limbs)(n=213,263,46,55)-2.05 ± 1.04-2.15 ± 1.00-1.96 ± 1.07-2.11 ± 1.18
Week 52:Erythema(Upper limbs)(n=194,239,38,42)-1.99 ± 1.07-2.15 ± 1.04-1.92 ± 1.08-2.07 ± 1.28
Week 2:Erythema(Trunk)(n=369,367,73,76)-0.47 ± 0.69-0.59 ± 0.70-0.14 ± 0.58-0.25 ± 0.66
Week 4:Erythema(Trunk)(n=363,366,74,75)-0.86 ± 0.90-1.04 ± 0.90-0.46 ± 0.91-0.31 ± 0.88
Week 8:Erythema(Trunk)(n=354,356,74,76)-1.18 ± 1.09-1.56 ± 1.07-0.69 ± 1.05-0.34 ± 1.01
Week 12:Erythema(Trunk)(n=347,348,74,76)-1.41 ± 1.19-1.82 ± 1.10-0.72 ± 1.08-0.42 ± 1.02
Week 16:Erythema(Trunk)(n=340,345,74,76)-1.58 ± 1.25-1.99 ± 1.17-0.88 ± 1.17-0.50 ± 1.09
Week 20:Erythema(Trunk)(n=327,338,74,76)-1.80 ± 1.25-2.12 ± 1.12-1.36 ± 1.18-1.21 ± 1.16
Week 28:Erythema(Trunk)(n=305,327,69,72)-1.94 ± 1.20-2.12 ± 1.17-1.88 ± 1.28-1.94 ± 1.32
Week 40:Erythema(Trunk)(n=213,263,46,55)-2.26 ± 1.04-2.31 ± 1.12-2.28 ± 1.11-2.45 ± 1.12
Week 52:Erythema(Trunk)(n=194,239,38,42)-2.19 ± 1.13-2.36 ± 1.03-2.29 ± 1.18-2.48 ± 1.06
Week 2:Erythema(Lower limbs)(n=369,367,73,76)-0.40 ± 0.66-0.55 ± 0.68-0.10 ± 0.48-0.26 ± 0.62
Week 4:Erythema(Lower limbs)(n=363,366,74,75)-0.84 ± 0.85-1.07 ± 0.87-0.42 ± 0.72-0.36 ± 0.80
Week 8:Erythema(Lower limbs)(n=354,356,74,76)-1.25 ± 1.05-1.57 ± 1.04-0.61 ± 0.89-0.45 ± 0.87
Week 12:Erythema(Lower limbs)(n=347,348,74,76)-1.46 ± 1.12-1.85 ± 1.12-0.66 ± 0.95-0.57 ± 1.10
Week 16:Erythema(Lower limbs)(n=340,345,74,76)-1.68 ± 1.20-2.00 ± 1.18-0.74 ± 1.07-0.71 ± 1.13
Week 20:Erythema(Lower limbs)(n=327,338,74,76)-1.84 ± 1.18-2.15 ± 1.16-1.34 ± 1.20-1.39 ± 1.06
Week 28:Erythema(Lower limbs)(n=305,327,69,72)-1.98 ± 1.18-2.21 ± 1.22-1.80 ± 1.18-2.19 ± 1.15
Week 40:Erythema(Lower limbs)(n=213,263,46,55)-2.38 ± 1.05-2.46 ± 1.08-2.17 ± 1.18-2.55 ± 1.09
Week 52:Erythema(Lower limbs)(n=194,239,38,42)-2.32 ± 1.12-2.44 ± 1.09-2.39 ± 1.17-2.52 ± 1.17
Week 2:Induration(Head\Neck)(n=369,367,73,76)-0.36 ± 0.72-0.51 ± 0.76-0.12 ± 0.55-0.14 ± 0.51
Week 4:Induration(Head\Neck)(n=363,366,74,75)-0.81 ± 0.96-0.97 ± 0.97-0.38 ± 0.81-0.29 ± 0.71
Week 8:Induration(Head\Neck)(n=354,356,74,76)-1.05 ± 1.12-1.27 ± 1.10-0.62 ± 1.02-0.36 ± 0.87
Week 12:Induration(Head\Neck)(n=347,348,74,76)-1.18 ± 1.21-1.42 ± 1.15-0.64 ± 1.07-0.34 ± 0.93
Week 16:Induration(Head\Neck)(n=340,345,74,76)-1.20 ± 1.20-1.45 ± 1.17-0.58 ± 1.09-0.47 ± 0.97
Week 20:Induration(Head\Neck)(n=327,338,74,76)-1.33 ± 1.17-1.54 ± 1.13-1.14 ± 1.00-1.11 ± 1.04
Week 28:Induration(Head\Neck)(n=305,327,69,72)-1.41 ± 1.14-1.55 ± 1.14-1.41 ± 1.15-1.44 ± 1.12
Week 40:Induration(Head\Neck)(n=213,263,46,55)-1.67 ± 1.12-1.66 ± 1.15-1.78 ± 1.11-1.73 ± 1.03
Week 52:Induration(Head\Neck)(n=194,239,38,42)-1.64 ± 1.12-1.72 ± 1.09-1.74 ± 1.16-1.83 ± 1.08
Week 2:Induration(Upper limbs)(n=369,367,73,76)-0.42 ± 0.65-0.54 ± 0.70-0.12 ± 0.47-0.33 ± 0.62
Week 4:Induration(Upper limbs)(n=363,366,74,75)-0.87 ± 0.85-1.07 ± 0.93-0.26 ± 0.74-0.44 ± 0.66
Week 8:Induration(Upper limbs)(n=354,356,74,76)-1.18 ± 1.01-1.46 ± 1.12-0.53 ± 0.89-0.53 ± 0.66
Week 12:Induration(Upper limbs)(n=347,348,74,76)-1.42 ± 1.09-1.61 ± 1.14-0.57 ± 0.98-0.64 ± 0.86
Week 16:Induration(Upper limbs)(n=340,345,74,76)-1.51 ± 1.19-1.68 ± 1.20-0.59 ± 1.19-0.70 ± 0.91
Week 20:Induration(Upper limbs)(n=327,338,74,76)-1.64 ± 1.17-1.79 ± 1.20-1.23 ± 1.10-1.49 ± 1.14
Week 28:Induration(Upper limbs)(n=305,327,69,72)-1.69 ± 1.13-1.79 ± 1.23-1.55 ± 1.18-1.94 ± 1.24
Week 40:Induration(Upper limbs)(n=213,263,46,55)-2.04 ± 1.06-2.05 ± 1.09-1.91 ± 1.15-2.20 ± 1.11
Week 52:Induration(Upper limbs)(n=194,239,38,42)-2.00 ± 1.09-2.10 ± 1.02-1.87 ± 1.09-2.29 ± 1.13
Week 2:Induration(Trunk)(n=369,367,73,76)-0.36 ± 0.64-0.50 ± 0.70-0.16 ± 0.47-0.26 ± 0.60
Week 4:Induration(Trunk)(n=363,366,74,75)-0.79 ± 0.89-1.01 ± 0.94-0.42 ± 0.91-0.28 ± 0.81
Week 8:Induration(Trunk)(n=354,356,74,76)-1.15 ± 1.11-1.54 ± 1.10-0.59 ± 1.06-0.38 ± 0.92
Week 12:Induration(Trunk)(n=347,348,74,76)-1.40 ± 1.20-1.79 ± 1.17-0.58 ± 1.16-0.43 ± 1.04
Week 16:Induration(Trunk)(n=340,345,74,76)-1.52 ± 1.31-1.94 ± 1.19-0.68 ± 1.26-0.54 ± 1.10
Week 20:Induration(Trunk)(n=327,338,74,76)-1.72 ± 1.28-2.04 ± 1.14-1.28 ± 1.21-1.38 ± 1.13
Week 28:Induration(Trunk)(n=305,327,69,72)-1.83 ± 1.21-2.07 ± 1.16-1.74 ± 1.29-1.94 ± 1.28
Week 40:Induration(Trunk)(n=213,263,46,55)-2.20 ± 1.09-2.25 ± 1.13-2.22 ± 1.15-2.29 ± 1.12
Week 52:Induration(Trunk)(n=194,239,38,42)-2.17 ± 1.15-2.32 ± 1.03-2.18 ± 1.14-2.24 ± 1.19
Week 2:Induration(Lower limbs)(n=369,367,73,76)-0.35 ± 0.65-0.51 ± 0.70-0.14 ± 0.54-0.26 ± 0.53
Week 4:Induration(Lower limbs)(n=363,366,74,75)-0.80 ± 0.88-1.06 ± 0.96-0.31 ± 0.76-0.40 ± 0.75
Week 8:Induration(Lower limbs)(n=354,356,74,76)-1.23 ± 1.09-1.59 ± 1.15-0.45 ± 0.98-0.41 ± 0.73
Week 12:Induration(Lower limbs)(n=347,348,74,76)-1.46 ± 1.17-1.86 ± 1.20-0.50 ± 1.10-0.50 ± 0.95
Week 16:Induration(Lower limbs)(n=340,345,74,76)-1.63 ± 1.26-1.97 ± 1.25-0.55 ± 1.21-0.59 ± 0.98
Week 20:Induration(Lower limbs)(n=327,338,74,76)-1.76 ± 1.23-2.12 ± 1.21-1.19 ± 1.24-1.46 ± 1.00
Week 28:Induration(Lower limbs)(n=305,327,69,72)-1.87 ± 1.22-2.19 ± 1.27-1.58 ± 1.39-2.07 ± 1.20
Week 40:Induration(Lower limbs)(n=213,263,46,55)-2.31 ± 1.10-2.43 ± 1.09-2.15 ± 1.23-2.40 ± 0.97
Week 52:Induration(Lower limbs)(n=194,239,38,42)-2.30 ± 1.17-2.40 ± 1.08-2.26 ± 1.25-2.29 ± 1.22
Week 2:Scaling(Head\Neck)(n=369,367,73,76)-0.53 ± 0.86-0.65 ± 0.83-0.14 ± 0.61-0.20 ± 0.63
Week 4:Scaling(Head\Neck)(n=363,366,74,75)-0.92 ± 1.07-1.13 ± 1.05-0.47 ± 0.95-0.36 ± 0.82
Week 8:Scaling(Head\Neck)(n=354,356,74,76)-1.20 ± 1.17-1.44 ± 1.18-0.65 ± 1.05-0.51 ± 0.96
Week 12:Scaling(Head\Neck)(n=347,348,74,76)-1.37 ± 1.25-1.60 ± 1.22-0.70 ± 1.07-0.53 ± 1.06
Week 16:Scaling(Head\Neck)(n=340,345,74,76)-1.34 ± 1.29-1.66 ± 1.22-0.73 ± 1.24-0.62 ± 1.23
Week 20:Scaling(Head\Neck)(n=327,338,74,76)-1.49 ± 1.21-1.69 ± 1.23-1.36 ± 1.14-1.28 ± 1.24
Week 28:Scaling(Head\Neck)(n=305,327,69,72)-1.54 ± 1.17-1.70 ± 1.20-1.62 ± 1.26-1.64 ± 1.19
Week 40:Scaling(Head\Neck)(n=213,263,46,55)-1.70 ± 1.21-1.83 ± 1.20-1.93 ± 1.32-1.76 ± 1.29
Week 52:Scaling(Head\Neck)(n=194,239,38,42)-1.71 ± 1.11-1.86 ± 1.19-2.00 ± 1.21-2.00 ± 1.23
Week 2:Scaling(Upper limbs)(n=369,367,73,76)-0.51 ± 0.79-0.60 ± 0.73-0.22 ± 0.58-0.43 ± 0.62
Week 4:Scaling(Upper limbs)(n=363,366,74,75)-0.92 ± 0.92-1.12 ± 0.98-0.47 ± 0.85-0.52 ± 0.81
Week 8:Scaling(Upper limbs)(n=354,356,74,76)-1.23 ± 1.07-1.47 ± 1.13-0.61 ± 0.90-0.59 ± 0.88
Week 12:Scaling(Upper limbs)(n=347,348,74,76)-1.39 ± 1.19-1.65 ± 1.18-0.74 ± 1.02-0.70 ± 0.91
Week 16:Scaling(Upper limbs)(n=340,345,74,76)-1.47 ± 1.26-1.73 ± 1.24-0.74 ± 1.23-0.68 ± 1.00
Week 20:Scaling(Upper limbs)(n=327,338,74,76)-1.63 ± 1.19-1.76 ± 1.23-1.38 ± 1.18-1.42 ± 1.00
Week 28:Scaling(Upper limbs)(n=305,327,69,72)-1.69 ± 1.22-1.82 ± 1.30-1.57 ± 1.25-1.71 ± 1.24
Week 40:Scaling(Upper limbs)(n=213,263,46,55)-1.93 ± 1.25-2.07 ± 1.18-2.02 ± 1.24-1.95 ± 1.24
Week 52:Scaling(Upper limbs)(n=194,239,38,42)-1.92 ± 1.21-2.13 ± 1.14-1.95 ± 1.16-1.95 ± 1.27
Week 2:Scaling(Trunk)(n=369,367,73,76)-0.50 ± 0.75-0.57 ± 0.78-0.33 ± 0.60-0.32 ± 0.66
Week 4:Scaling(Trunk)(n=363,366,74,75)-0.85 ± 0.97-1.08 ± 0.99-0.54 ± 0.97-0.43 ± 0.96
Week 8:Scaling(Trunk)(n=354,356,74,76)-1.27 ± 1.15-1.59 ± 1.17-0.74 ± 1.11-0.46 ± 0.99
Week 12:Scaling(Trunk)(n=347,348,74,76)-1.48 ± 1.23-1.81 ± 1.18-0.80 ± 1.16-0.50 ± 1.03
Week 16:Scaling(Trunk)(n=340,345,74,76)-1.61 ± 1.28-1.95 ± 1.16-0.93 ± 1.24-0.66 ± 1.09
Week 20:Scaling(Trunk)(n=327,338,74,76)-1.81 ± 1.26-2.04 ± 1.12-1.46 ± 1.21-1.39 ± 1.16
Week 28:Scaling(Trunk)(n=305,327,69,72)-1.92 ± 1.18-2.07 ± 1.19-1.80 ± 1.37-1.88 ± 1.29
Week 40:Scaling(Trunk)(n=213,263,46,55)-2.15 ± 1.20-2.25 ± 1.10-2.33 ± 1.16-2.18 ± 1.20
Week 52:Scaling(Trunk)(n=194,239,38,42)-2.13 ± 1.20-2.30 ± 1.03-2.18 ± 1.11-2.14 ± 1.18
Week 2:Scaling(Lower limbs)(n=369,367,73,76)-0.49 ± 0.74-0.56 ± 0.75-0.32 ± 0.66-0.36 ± 0.69
Week 4:Scaling(Lower limbs)(n=363,366,74,75)-0.88 ± 0.97-1.10 ± 1.01-0.46 ± 0.83-0.56 ± 0.84
Week 8:Scaling(Lower limbs)(n=354,356,74,76)-1.34 ± 1.15-1.69 ± 1.19-0.69 ± 0.99-0.62 ± 0.92
Week 12:Scaling(Lower limbs)(n=347,348,74,76)-1.52 ± 1.23-1.97 ± 1.20-0.73 ± 1.08-0.72 ± 1.11
Week 16:Scaling(Lower limbs)(n=340,345,74,76)-1.64 ± 1.29-2.05 ± 1.28-0.86 ± 1.20-0.68 ± 1.19
Week 20:Scaling(Lower limbs)(n=327,338,74,76)-1.84 ± 1.26-2.16 ± 1.29-1.59 ± 1.12-1.53 ± 1.23
Week 28:Scaling(Lower limbs)(n=305,327,69,72)-1.96 ± 1.27-2.22 ± 1.33-1.81 ± 1.26-2.15 ± 1.26
Week 40:Scaling(Lower limbs)(n=213,263,46,55)-2.31 ± 1.21-2.48 ± 1.16-2.22 ± 1.26-2.38 ± 1.24
Week 52:Scaling(Lower limbs)(n=194,239,38,42)-2.31 ± 1.23-2.49 ± 1.12-2.29 ± 1.27-2.33 ± 1.32
SecondaryPercent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline, Week 2, 4, 8, 12,16, 20, 28, 40, 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
percent changeCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Change at Week 2-18.21 ± 1.10-22.15 ± 1.10-5.07 ± 2.46-11.41 ± 2.42
Change at Week 4-34.62 ± 1.44-42.21 ± 1.44-14.25 ± 3.20-14.41 ± 3.17
Change at Week 8-50.36 ± 1.64-61.31 ± 1.64-22.18 ± 3.64-17.40 ± 3.59
Change at Week 12-57.96 ± 1.73-69.63 ± 1.73-24.39 ± 3.82-19.37 ± 3.77
Change at Week 16-62.06 ± 1.81-73.21 ± 1.80-25.91 ± 3.97-22.50 ± 3.92
Change at Week 20-67.66 ± 1.60-77.82 ± 1.59-51.51 ± 3.48-57.68 ± 3.44
Change at Week 28-71.71 ± 1.59-79.17 ± 1.56-65.89 ± 3.40-76.28 ± 3.36
Change at Week 40-67.88 ± 1.90-75.71 ± 1.83-60.94 ± 4.06-72.19 ± 3.95
Change at Week 52-63.98 ± 2.10-71.82 ± 2.02-56.64 ± 4.54-69.52 ± 4.42
SecondaryTotal Body Surface Area (BSA) With Psoriasis

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline, Week 2, 4, 8,16, 20, 28, 40, 52
Reported as:
Mean · percentage of BSA
Total Body Surface Area (BSA) With Psoriasis
percentage of BSACP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=376,374,74,76)30.94 ± 17.9728.49 ± 16.2730.10 ± 17.9730.27 ± 17.98
Week 2 (n=369,367,73,76)28.25 ± 17.1926.40 ± 16.2730.63 ± 18.3629.59 ± 17.47
Week 4 (n=363,366,74,75)25.09 ± 17.3921.98 ± 16.4829.46 ± 18.5029.48 ± 17.49
Week 8 (n=354,356,74,76)19.03 ± 15.5915.63 ± 15.3826.95 ± 17.7828.07 ± 18.12
Week 12 (n=354,356,74,76)15.54 ± 15.8811.46 ± 14.2325.67 ± 18.5126.80 ± 17.99
Week 16 (n=340,345,74,76)13.40 ± 16.309.11 ± 12.6224.95 ± 19.2726.04 ± 17.73
Week 20 (n=327,338,74,76)11.56 ± 15.607.16 ± 11.1118.71 ± 16.8917.65 ± 16.84
Week 28 (n=305,327,69,72)9.24 ± 13.296.04 ± 10.7011.23 ± 13.239.53 ± 15.33
Week 40 (n=213,263,46,55)5.24 ± 9.663.66 ± 7.686.91 ± 13.564.52 ± 8.56
Week 52 (n=194,239,38,42)4.37 ± 7.693.32 ± 7.234.91 ± 7.483.32 ± 5.62
SecondaryPercent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
percent changeCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Change at Week 2-7.62 ± 0.91-7.80 ± 0.911.77 ± 2.04-1.13 ± 2.00
Change at Week 4-18.73 ± 1.44-23.68 ± 1.44-2.52 ± 3.21-1.70 ± 3.18
Change at Week 8-36.67 ± 1.86-46.76 ± 1.86-10.57 ± 4.12-4.57 ± 4.07
Change at Week 12-47.94 ± 1.98-60.67 ± 1.98-15.27 ± 4.37-7.55 ± 4.32
Change at Week 16-54.90 ± 2.08-67.16 ± 2.07-18.31 ± 4.56-8.13 ± 4.50
Change at Week 20-61.63 ± 1.98-74.17 ± 1.97-37.33 ± 4.30-38.93 ± 4.24
Change at Week 28-68.41 ± 1.84-77.92 ± 1.81-57.91 ± 3.94-67.84 ± 3.88
Change at Week 40-69.93 ± 1.86-77.78 ± 1.79-61.08 ± 3.98-70.79 ± 3.86
Change at Week 52-71.23 ± 1.86-77.20 ± 1.76-63.88 ± 4.03-76.60 ± 3.88
SecondaryPercentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least a 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported.

Time frame:
Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 29.31 (6.37 to 12.25)12.30 (8.97 to 15.63)2.70 (0.00 to 6.40)6.58 (1.01 to 12.15)
Week 428.19 (23.64 to 32.74)41.44 (36.45 to 46.44)9.46 (2.79 to 16.13)11.84 (4.58 to 19.11)
Week 851.60 (46.54 to 56.65)66.84 (62.07 to 71.62)18.92 (10.00 to 27.84)14.47 (6.56 to 22.38)
Week 1261.17 (56.24 to 66.10)72.99 (68.49 to 77.49)25.68 (15.72 to 35.63)15.79 (7.59 to 23.99)
Week 1663.30 (58.43 to 68.17)74.33 (69.90 to 78.76)29.73 (19.32 to 40.14)23.68 (14.13 to 33.24)
Week 2067.55 (62.82 to 72.29)78.34 (74.17 to 82.52)56.76 (45.47 to 68.04)63.16 (52.31 to 74.00)
Week 2868.88 (64.20 to 73.56)77.27 (73.03 to 81.52)70.27 (59.86 to 80.68)76.32 (66.76 to 85.87)
Week 4053.46 (48.42 to 58.50)67.65 (62.91 to 72.39)56.76 (45.47 to 68.04)69.74 (59.41 to 80.07)
Week 5248.67 (43.62 to 53.72)62.03 (57.11 to 66.95)48.65 (37.26 to 60.04)52.63 (41.41 to 63.86)
SecondaryPercentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response is reported.

Time frame:
Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 20.27 (0.00 to 0.79)0.27 (0.00 to 0.79)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 42.66 (1.03 to 4.29)2.67 (1.04 to 4.31)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 89.04 (6.14 to 11.94)15.24 (11.60 to 18.88)4.05 (0.00 to 8.55)2.63 (0.00 to 6.23)
Week 1218.09 (14.19 to 21.98)29.68 (25.05 to 34.31)5.41 (0.25 to 10.56)3.95 (0.00 to 8.33)
Week 1624.47 (20.12 to 28.81)38.77 (33.83 to 43.71)9.46 (2.79 to 16.13)3.95 (0.00 to 8.33)
Week 2029.52 (24.91 to 34.13)41.98 (36.98 to 46.98)14.86 (6.76 to 22.97)14.47 (6.56 to 22.38)
Week 2829.52 (24.91 to 34.13)44.12 (39.09 to 49.15)31.08 (20.54 to 41.63)46.05 (34.85 to 57.26)
Week 4028.99 (24.40 to 33.58)40.11 (35.14 to 45.07)27.03 (16.91 to 37.15)43.42 (32.28 to 54.56)
Week 5227.39 (22.89 to 31.90)36.36 (31.49 to 41.24)22.97 (13.39 to 32.56)32.89 (22.33 to 43.46)
SecondaryPercentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked).

Time frame:
Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 2 (n=369,367,73,76)0.54 (0.00 to 1.29)1.09 (0.03 to 2.15)1.37 (0.00 to 4.04)1.32 (0.00 to 3.88)
Week 4 (n=363,366,74,75)0.83 (0.00 to 1.76)1.09 (0.03 to 2.16)2.70 (0.00 to 6.40)4.00 (0.00 to 8.43)
Week 8 (n=354,356,74,76)1.13 (0.03 to 2.23)0.84 (0.00 to 1.79)4.05 (0.00 to 8.55)7.89 (1.83 to 13.96)
Week 12 (n=347,348,74,76)1.15 (0.03 to 2.28)1.15 (0.03 to 2.27)8.11 (1.89 to 14.33)7.89 (1.83 to 13.96)
Week 16 (n=340,345,74,76)1.47 (0.19 to 2.75)1.16 (0.03 to 2.29)10.81 (3.74 to 17.89)9.21 (2.71 to 15.71)
Week 20 (n=327,338,74,76)0.61 (0.00 to 1.46)0.30 (0.00 to 0.87)4.05 (0.00 to 8.55)1.32 (0.00 to 3.88)
Week 28 (n=305,327,69,72)0.66 (0.00 to 1.56)0.31 (0.00 to 0.90)2.90 (0.00 to 6.86)0.00 (0.00 to 0.00)
Week 40 (n=213,263,46,55)0.00 (0.00 to 0.00)0.76 (0.00 to 1.81)2.17 (0.00 to 6.39)0.00 (0.00 to 0.00)
Week 52 (n=194,239,38,42)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryNail Psoriasis Severity Index (NAPSI) Score

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.'n' signifies participants evaluable at specified time point for each arm.

Time frame:
Baseline, Week 8, 16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Nail Psoriasis Severity Index (NAPSI) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=240,226,43,55)27.31 ± 20.4526.22 ± 20.3525.40 ± 17.6026.78 ± 18.67
Week 8 (n=226,214,43,55)22.36 ± 19.8321.88 ± 19.2921.86 ± 17.2425.75 ± 18.29
Week 16 (n=218,205,43,55)17.17 ± 16.8616.58 ± 18.1322.53 ± 18.9625.69 ± 18.37
Week 20 (n=208,206,43,55)15.03 ± 16.9714.02 ± 16.7021.44 ± 18.3224.29 ± 17.30
Week 28 (n=193,197,40,53)11.77 ± 15.2911.78 ± 15.9015.93 ± 16.0617.77 ± 15.90
Week 40 (n=118,148,26,39)10.11 ± 15.717.95 ± 13.577.73 ± 11.8011.31 ± 13.41
Week 52 (n=108,137,21,30)9.06 ± 13.437.92 ± 14.325.29 ± 7.127.53 ± 9.35
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'n' signifies participants evaluable at specified time point for each arm.

Time frame:
Baseline,Week 8, 16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Change at Week 8(n=226,214,43,55)-4.33 ± 11.30-4.21 ± 10.80-3.53 ± 10.35-1.04 ± 8.54
Change at Week 16(n=218,205,43,55)-8.74 ± 14.02-9.36 ± 13.60-2.86 ± 12.72-1.09 ± 11.07
Change at Week 20(n=208,206,43,55)-10.61 ± 15.48-11.50 ± 14.74-3.95 ± 14.31-2.49 ± 10.63
Change at Week 28(n=193,197,40,53)-13.86 ± 14.96-14.30 ± 14.75-9.45 ± 17.63-8.91 ± 12.90
Change at Week 40(n=118,148,26,39)-16.45 ± 14.80-18.11 ± 15.84-21.50 ± 17.28-15.33 ± 12.60
Change at Week 52(n=108,137,21,30)-17.08 ± 15.36-18.13 ± 15.27-23.29 ± 19.97-19.17 ± 13.88
SecondaryNumber of Affected Nails

Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number of psoriasis affected nails (presence of psoriatic manifestations on the nail matrix / nail bed) were assessed and reported. 'N' (number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.

Time frame:
Baseline, Week 8, 16, 20, 28, 40, 52
Reported as:
Mean · nails
Number of Affected Nails
nailsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=240,226,43,55)7.45 ± 3.037.23 ± 3.207.21 ± 2.777.36 ± 3.08
Week 8 (n=226,214,43,55)6.50 ± 3.516.65 ± 3.616.98 ± 3.117.56 ± 2.99
Week 16 (n=218,204,43,55)5.83 ± 3.585.37 ± 3.916.79 ± 3.537.56 ± 3.02
Week 20 (n=207,206,43,55)5.19 ± 3.664.86 ± 3.896.44 ± 3.807.42 ± 2.99
Week 28 (n=193,197,40,53)4.42 ± 3.744.23 ± 3.855.38 ± 4.116.40 ± 3.62
Week 40 (n=118,148,26,39)3.79 ± 3.753.03 ± 3.533.12 ± 3.564.41 ± 3.89
Week 52 (n=108,137,21,30)3.63 ± 3.702.85 ± 3.732.86 ± 3.453.67 ± 3.74
SecondaryPercent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'N' (number of participants analyzed) signifies participants with baseline nail psoriasis and who were unique in longitudinal model.

Time frame:
Baseline,Week 8,16, 20, 28, 40, 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52
percent changeCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Percent Change at Week 8-11.95 ± 6.560.55 ± 6.73-14.70 ± 15.0611.37 ± 13.31
Percent Change at Week 16-21.56 ± 7.65-25.87 ± 7.83-10.70 ± 17.3231.51 ± 15.32
Percent Change at Week 20-24.02 ± 9.50-35.56 ± 9.65-12.19 ± 21.3037.72 ± 18.83
Percent Change Week 28-46.40 ± 6.80-53.80 ± 6.85-31.97 ± 15.175.38 ± 13.34
Percent Change Week 40-54.22 ± 5.70-60.39 ± 5.39-67.71 ± 12.43-51.65 ± 10.52
Percent Change Week 52-56.38 ± 5.55-65.06 ± 5.17-69.87 ± 12.46-72.94 ± 10.57
SecondaryPercentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.

Time frame:
Week 8, 16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 810.83 (6.90 to 14.77)11.95 (7.72 to 16.18)6.98 (0.00 to 14.59)1.82 (0.00 to 5.35)
Week 1618.75 (13.81 to 23.69)26.99 (21.20 to 32.78)16.28 (5.24 to 27.31)5.45 (0.00 to 11.46)
Week 2024.17 (18.75 to 29.58)33.19 (27.05 to 39.33)23.26 (10.63 to 35.88)7.27 (0.41 to 14.14)
Week 2834.58 (28.57 to 40.60)39.82 (33.44 to 46.21)32.56 (18.55 to 46.56)18.18 (7.99 to 28.38)
Week 4024.58 (19.14 to 30.03)40.71 (34.30 to 47.11)44.19 (29.34 to 59.03)38.18 (25.34 to 51.02)
Week 5223.75 (18.37 to 29.13)40.71 (34.30 to 47.11)39.53 (24.92 to 54.15)29.09 (17.09 to 41.09)
SecondaryPercentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.

Time frame:
Week 8,16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 87.92 (4.50 to 11.33)7.52 (4.08 to 10.96)2.33 (0.00 to 6.83)1.82 (0.00 to 5.35)
Week 1610.42 (6.55 to 14.28)16.37 (11.55 to 21.20)11.63 (2.05 to 21.21)5.45 (0.00 to 11.46)
Week 2014.17 (9.75 to 18.58)21.68 (16.31 to 27.05)16.28 (5.24 to 27.31)3.64 (0.00 to 8.58)
Week 2818.75 (13.81 to 23.69)25.22 (19.56 to 30.88)23.26 (10.63 to 35.88)12.73 (3.92 to 21.54)
Week 4017.08 (12.32 to 21.84)25.66 (19.97 to 31.36)23.26 (10.63 to 35.88)20.00 (9.43 to 30.57)
Week 5217.08 (12.32 to 21.84)29.65 (23.69 to 35.60)20.93 (8.77 to 33.09)20.00 (9.43 to 30.57)
SecondaryItch Severity Item (ISI) Score

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

Time frame:
Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Itch Severity Item (ISI) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, Then CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=364,361,74,71)5.70 ± 2.655.51 ± 2.645.32 ± 2.665.08 ± 2.58
Week 2 (n=369,367,73,76)3.88 ± 2.663.47 ± 2.615.01 ± 2.724.66 ± 2.50
Week 4 (n=364,365,74,75)3.22 ± 2.612.45 ± 2.364.64 ± 3.054.83 ± 2.64
Week 8 (n=354,354,74,76)2.79 ± 2.681.89 ± 2.334.77 ± 2.964.95 ± 2.79
Week 12 (n=347,349,74,76)2.55 ± 2.751.77 ± 2.384.46 ± 2.945.01 ± 2.95
Week 16 (n=340,345,74,76)2.31 ± 2.591.68 ± 2.384.84 ± 3.195.17 ± 3.07
Week 20 (n=327,338,74,76)2.06 ± 2.521.44 ± 2.162.28 ± 2.472.42 ± 2.43
Week 28 (n=304,326,68,72)2.05 ± 2.531.52 ± 2.211.93 ± 2.511.51 ± 2.42
Week 40 (n=212,262,46,55)1.58 ± 2.301.34 ± 2.011.89 ± 2.641.15 ± 2.09
Week52 (n=194,238,38,42)1.62 ± 2.311.15 ± 1.801.82 ± 2.551.19 ± 1.99
SecondaryChange From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline, Week 2, 4, 8,12,16, 20, 28 , 40, 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Change at Week 2-1.72 ± 0.11-2.05 ± 0.11-0.44 ± 0.24-0.63 ± 0.25
Change at Week 4-2.39 ± 0.12-3.05 ± 0.12-0.78 ± 0.26-0.43 ± 0.26
Change at Week 8-2.84 ± 0.13-3.63 ± 0.13-0.64 ± 0.27-0.31 ± 0.28
Change at Week 12-2.99 ± 0.13-3.68 ± 0.13-0.95 ± 0.28-0.21 ± 0.29
Change at Week 16-3.15 ± 0.13-3.78 ± 0.13-0.58 ± 0.29-0.00 ± 0.30
Change at Week 20-3.37 ± 0.13-3.97 ± 0.13-3.13 ± 0.27-2.87 ± 0.28
Change at Week 28-3.35 ± 0.13-3.88 ± 0.13-3.32 ± 0.28-3.79 ± 0.29
Change at Week 40-3.23 ± 0.15-3.59 ± 0.15-2.97 ± 0.33-3.69 ± 0.32
Change at Week 52-3.03 ± 0.16-3.62 ± 0.15-2.71 ± 0.36-3.14 ± 0.36
SecondaryDermatology Life Quality Index (DLQI) Score

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Mean · units on a scale
Dermatology Life Quality Index (DLQI) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=376,371,74,76)13.22 ± 7.2112.69 ± 7.1813.05 ± 7.0912.12 ± 7.01
Week 2 (n=369,367,73,76)9.07 ± 6.518.02 ± 6.2510.37 ± 7.099.51 ± 5.86
Week 4 (n=362,365,74,75)7.54 ± 6.405.70 ± 5.489.61 ± 7.429.47 ± 6.45
Week 8 (n=352,354,74,76)6.44 ± 6.354.50 ± 5.378.99 ± 6.919.68 ± 6.45
Week 12 (n=346,346,74,76)5.91 ± 6.293.72 ± 5.038.28 ± 6.7410.25 ± 6.91
Week 16 (n=338,342,74,76)5.53 ± 5.933.55 ± 4.938.95 ± 8.1210.03 ± 7.33
Week 20 (n=327,338,74,76)4.82 ± 5.463.29 ± 4.804.91 ± 5.335.97 ± 6.07
Week 28 (n=301,324,68,70)4.50 ± 5.192.97 ± 4.653.78 ± 5.224.29 ± 6.20
Week 40 (n=210,256,46,54)3.27 ± 4.712.32 ± 4.004.30 ± 6.502.94 ± 4.85
Week 52 (n=194,238,38,42)3.25 ± 4.482.21 ± 3.874.32 ± 5.852.95 ± 5.07
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. Here 'N' (number of participants analyzed) signifies the unique participants in the longitudinal model.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Change at Week 2-3.98 ± 0.22-4.70 ± 0.22-2.56 ± 0.50-2.95 ± 0.49
Change at Week 4-5.50 ± 0.24-6.89 ± 0.24-3.35 ± 0.53-3.00 ± 0.53
Change at Week 8-6.63 ± 0.27-8.08 ± 0.27-3.97 ± 0.59-2.78 ± 0.58
Change at Week 12-7.03 ± 0.28-8.73 ± 0.28-4.67 ± 0.61-2.21 ± 0.61
Change at Week 16-7.24 ± 0.29-8.95 ± 0.30-4.01 ± 0.64-2.44 ± 0.64
Change at Week 20-7.93 ± 0.28-9.21 ± 0.27-8.05 ± 0.60-6.49 ± 0.59
Change at Week 28-8.20 ± 0.29-9.44 ± 0.29-8.80 ± 0.63-8.07 ± 0.62
Change at Week 40-8.23 ± 0.31-9.38 ± 0.30-7.75 ± 0.67-8.31 ± 0.65
Change at Week 52-8.18 ± 0.32-9.43 ± 0.30-7.30 ± 0.70-8.01 ± 0.67
Secondary36-Item Short-Form Health Survey Version 2, Acute (SF-36)

36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

Time frame:
Baseline, Week 16, 28, 52
Reported as:
Mean · units on a scale
36-Item Short-Form Health Survey Version 2, Acute (SF-36)
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline:Physical Health(n=375,371,74,76)46.80 ± 9.5947.25 ± 9.0547.39 ± 9.4247.90 ± 9.57
Baseline: Mental Health(n=375,371,74,76)43.24 ± 12.0443.40 ± 12.5442.98 ± 12.4343.30 ± 12.57
Week 16:Physical Health(n=337,337,74,76)51.11 ± 8.1251.40 ± 8.4550.03 ± 9.5648.39 ± 10.29
Week 16:Mental Health (n=337,337,74,76)47.32 ± 10.6149.07 ± 9.7245.96 ± 11.5644.65 ± 11.62
Week 28:Physical Health(n=300,322,68,72)51.85 ± 7.8151.79 ± 8.7052.27 ± 8.1850.34 ± 9.58
Week 28:Mental Health(n=300,322,68,72)47.81 ± 10.8349.52 ± 10.2948.06 ± 9.1746.67 ± 10.86
Week 52:Physical health(n=194,237,38,42)52.38 ± 7.2552.94 ± 7.9253.00 ± 7.6651.48 ± 8.71
Week 52:Mental Health(n=194,237,38,42)49.46 ± 10.1849.99 ± 9.4546.44 ± 9.8450.87 ± 8.31
SecondaryHospital Anxiety and Depression Scale (HADS) Score

HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale and 7 items comprising the depression subscale. Each item has response options ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total HADS score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 8, 16, 28, 52
Reported as:
Mean · units on a scale
Hospital Anxiety and Depression Scale (HADS) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline:Anxiety subcale(n=376,371,74,76)7.05 ± 4.146.94 ± 4.367.72 ± 4.316.38 ± 4.14
Baseline:Depression subcale(n=376,371,74,76)6.00 ± 4.425.64 ± 4.165.85 ± 4.385.51 ± 3.79
Week 8:Anxiety subcale(n=351,354,74,76)5.65 ± 4.005.15 ± 3.596.45 ± 3.816.47 ± 4.06
Week 8:Depression subcale(n=351,354,74,76)4.68 ± 3.913.72 ± 3.354.95 ± 4.025.03 ± 3.75
Week 16:Anxiety(n=337,340,74,76)5.43 ± 4.085.18 ± 4.005.43 ± 3.805.55 ± 4.22
Week 16:Depression(n=337,340,74,76)4.36 ± 4.063.50 ± 3.324.49 ± 4.205.21 ± 3.94
Week 28:Anxiety(n=300,322,68,72)4.86 ± 3.924.71 ± 3.854.96 ± 4.265.10 ± 4.11
Week 28:Depression(n=300,322,68,72)4.03 ± 3.973.20 ± 3.293.68 ± 3.914.65 ± 3.82
Week 52:Anxiety(n=194,237,38,42)4.36 ± 3.944.32 ± 3.684.89 ± 4.574.10 ± 3.53
Week 52:Depression(n=194,237,38,42)3.62 ± 3.843.14 ± 3.223.29 ± 3.502.95 ± 3.11
SecondaryWork Limitation Questionnaire (WLQ) Index Score

WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands Scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).

Time frame:
Baseline, Week 8, 16, 28, 52
Reported as:
Mean · units on a scale
Work Limitation Questionnaire (WLQ) Index Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=324,318,66,68)7.77 ± 5.948.26 ± 6.597.63 ± 5.657.78 ± 6.32
Week 8 (n=293,302,63,61)6.89 ± 6.796.99 ± 6.687.04 ± 6.418.53 ± 7.11
Week 16 (n=278,292,64,61)6.28 ± 6.316.44 ± 6.487.27 ± 6.977.14 ± 6.46
Week 28 (n=249,277,56,61)5.93 ± 6.035.71 ± 5.646.11 ± 6.767.45 ± 7.27
Week 52 (n=164,205,31,38)5.86 ± 6.355.79 ± 6.036.48 ± 6.415.23 ± 5.97
SecondaryPercentage of Participants With Patient Global Assessment (PtGA) Scale Response

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).

Time frame:
Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Global Assessment (PtGA) Scale Response
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline:Clear(n=376,372,74,76)0000
Baseline:Almost Clear(n=376,372,74,76)0.5000
Baseline:Mild(n=376,372,74,76)4.33.02.72.6
Baseline:Moderate(n=376,372,74,76)33.232.841.934.2
Baseline:Severe(n=376,372,74,76)62.064.255.463.2
Week 2:Clear(n=369,366,73,76)0000
Week2:Almost Clear(n=369,366,73,76)2.22.21.40
Week2:Mild(n=369,366,73,76)13.621.012.37.9
Week2:Moderate(n=369,366,73,76)49.945.441.142.1
Week 2:Severe(n=369,366,73,76)34.431.445.250.0
Week 4:Clear(n=363,365,74,75)0.60.300
Week 4:Almost clear(n=363,365,74,75)7.413.75.40
Week 4:Mild(n=363,365,74,75)22.335.310.812.0
Week4:Moderate(n=363,365,74,75)46.333.445.941.3
Week 4:Severe(n=363,365,74,75)23.417.337.846.7
Week 8:Clear(n=352,354,74,76)1.74.24.10
Week 8:Almost clear(n=352,354,74,76)19.932.51.40
Week 8:Mild(n=352,354,74,76)29.530.816.210.5
Week 8:Moderate(n=352,354,74,76)32.122.647.340.8
Week 8:Severe(n=352,354,74,76)16.89.931.148.7
Week 12:Clear(n=346,345,74,76)4.311.02.70
Week 12:Almost Clear(n=346,345,74,76)30.143.88.12.6
Week 12:Mild(n=346,345,74,76)24.919.720.37.9
Week 12:Moderate(n=346,345,74,76)26.918.337.843.4
Week 12:Severe(n=346,345,74,76)13.97.231.146.1
Week 16:Clear(n=337,342,74,75)6.214.06.80
Week 16:Almost clear(n=337,342,74,75)30.941.82.72.7
Week 16:Mild(n=n=337,342,74,75)27.921.920.314.7
Week 16:Moderate(n=n=337,342,74,75)21.416.739.234.7
Week 16:Severe(n=n=337,342,74,75)13.65.631.148.0
Week 20:Clear(n=327,338,73,76)8.915.79.61.3
Week 20:Almost Clear(n=327,338,73,76)33.643.813.718.4
Week 20:Mild(n=327,338,73,76)25.421.339.734.2
Week 20:Moderate(n=327,338,73,76)23.512.728.830.3
Week 20:Severe(n=327,338,73,76)8.66.58.215.8
Week 28:Clear(n=300,324,68,72)11.321.319.112.5
Week 28:Almost Clear(n=300,324,68,72)34.343.536.843.1
Week 28:Mild(n=300,324,68,72)26.317.617.618.1
Week 28:Moderate(n=300,324,68,72)22.012.017.618.1
Week 28:Severe(n=300,324,68,72)6.05.68.88.3
Week 40:Clear(n=210,255,46,54)21.026.321.720.4
Week 40: Almost Clear(n=210,255,46,54)40.045.937.050.0
Week 40:Mild(n=210,255,46,54)22.916.919.613.0
Week 40:Moderate(n=210,255,46,54)12.98.613.09.3
Week 40:Severe(n=210,255,46,54)3.32.48.77.4
Week 52:Clear(n=194,238,38,42)14.426.926.321.4
Week 52:Almost Clear(n=194,238,38,42)44.845.426.352.4
Week 52:Mild(n=194,238,38,42)24.216.828.911.9
Week 52:Moderate(n=194,238,38,42)12.98.813.27.1
Week 52:Severe(n=194,238,38,42)3.62.15.37.1
SecondaryPercentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response

The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study treatment.

Time frame:
Week 16, 28, 52
Reported as:
Number · percentage of Participants
Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response
percentage of ParticipantsCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Week 16:Very satisfied(n=337,339,74,76)48.460.510.817.1
Week 16:Somewhat satisfied(n=337,339,74,76)24.923.920.314.5
Week 16:Slightly satisfied(n=337,339,74,76)8.05.610.813.2
Week16:Not satisfied/dissatisfied(n=337,339,74,76)4.73.817.615.8
Week 16:Slightly dissatisfied(n=337,339,74,76)3.31.56.83.9
Week 16:Somewhat dissatisfied(n=337,339,74,76)5.31.512.215.8
Week 16:Very dissatisfied(n=337,339,74,76)5.33.221.619.7
Week 28:Very satisfied(n=300,320,68,72)48.758.845.654.2
Week 28:Somewhat satisfied(n=300,320,68,72)28.026.325.019.4
Week 28:Slightly satisfied(n=300,320,68,72)11.05.611.89.7
Week28:Not satisfied/dissatisfied(n=300,320,68,72)3.02.54.44.2
Week 28:Slightly dissatisfied(n=300,320,68,72)3.32.25.95.6
Week 28:Somewhat dissatisfied(n=300,320,68,72)2.72.82.92.8
Week 28:Very dissatisfied(n=300,320,68,72)3.31.94.44.2
Week 52:Very satisfied(n=194,237,38,42)57.762.950.071.4
Week 52:Somewhat satisfied(n=194,237,38,42)29.427.828.916.7
Week 52:Slightly satisfied(n=194,237,38,42)6.24.610.54.8
Week52:Not satisfied/dissatisfied(n=194,237,38,42)1.51.32.62.4
Week 52:Slightly dissatisfied(n=194,237,38,42)1.51.702.4
Week 52:Somewhat dissatisfied(n=194,237,38,42)2.60.85.30
Week 52:Very dissatisfied(n=194,237,38,42)1.00.82.62.4
SecondaryJoint Pain Assessment (JPA) Score

The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain".

Time frame:
Baseline, Week 8,16, 28, 52
Reported as:
Mean · units on a scale
Joint Pain Assessment (JPA) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=376,372,74,76)3.79 ± 3.133.44 ± 3.093.45 ± 2.892.96 ± 3.05
Week 8 (n=351,354,74,76)2.50 ± 2.562.22 ± 2.582.86 ± 2.913.14 ± 3.00
Week 16 (n=336,340,74,76)2.24 ± 2.591.95 ± 2.412.88 ± 2.933.21 ± 3.16
Week 28 (n=300,320,68,72)2.25 ± 2.641.78 ± 2.402.15 ± 2.622.26 ± 2.64
Week 52 (n=193,235,38,42)1.88 ± 2.411.74 ± 2.302.00 ± 2.631.64 ± 2.59
SecondaryEuro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline, Week 16, 28, 40, 52
Reported as:
Mean · units on a scale
Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=376,372,74,76)0.76 ± 0.200.78 ± 0.180.79 ± 0.150.80 ± 0.19
Week 16 (n=337,340,74,76)0.85 ± 0.160.88 ± 0.140.82 ± 0.170.80 ± 0.20
Week 28 (n=300,322,68,72)0.86 ± 0.160.88 ± 0.150.88 ± 0.150.86 ± 0.16
Week 40 (n=210,256,46,54)0.90 ± 0.130.91 ± 0.120.91 ± 0.100.88 ± 0.18
Week 52 (n=194,237,38,42)0.89 ± 0.120.89 ± 0.140.90 ± 0.100.87 ± 0.17
SecondaryEuro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline,Week 16, 28, 40, 52
Reported as:
Mean · mm
Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)
mmCP-690,550 5mgCP-690,550 10 mgPlacebo, Then CP-690,550 5 mgPlacebo, Then CP-690,550 10 mg
Baseline (n=373,372,74,76)65.83 ± 24.0467.38 ± 24.2163.82 ± 23.6665.05 ± 25.63
Week 16 (n=337,339,74,76)76.19 ± 18.8078.43 ± 17.5972.24 ± 20.7670.14 ± 22.19
Week 28 (n=300,322,69,72)78.48 ± 17.4680.65 ± 15.3177.00 ± 20.7777.53 ± 17.49
Week 40 (n=210,255,46,54)81.40 ± 17.4282.27 ± 15.6979.70 ± 19.1782.78 ± 18.58
Week 52 (n=195,238,38,42)81.95 ± 15.9181.48 ± 15.5378.00 ± 19.1181.52 ± 20.60
SecondaryPsoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist and Rheumatologist. Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

Time frame:
Baseline, Week 16
Reported as:
Number · events
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional
eventsCP-690,550 5mgCP-690,550 10 mgPlacebo
Baseline:General Practitioner(n=45,45,24)452
Baseline:Dermatologist(n=45,45,24)444422
Baseline:Rheumatologist(n=45,45,24)000
Baseline:Cardiologist(n=45,45,24)000
Baseline:Gastroenterologist(n=45,45,24)010
Baseline:Psychiatrist(n=45,45,24)100
Baseline:Surgeon(n=45,45,24)001
Baseline:Nurse(n=45,45,24)15168
Baseline:Other(n=45,45,24)000
Week 16:General Practitioner(n=67,68,30)313417
Week 16:Dermatologist(n=67,68,30)25259
Week 16:Rheumatologist(n=67,68,30)312
Week 16:Cardiologist(n=67,68,30)501
Week 16:Gastroenterologist(n=67,68,30)111
Week 16:Psychiatrist(n=67,68,30)100
Week 16: Surgeon(n=67,68,30)522
Week 16:Nurse(n=67,68,30)14115
Week 16:Others(n=67,68,30)181416
SecondaryPsoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants (currently employed \[Emp\]) answered (Yes/No \[Y/N\]): "Were you absent or on sick leave from work due to psoriasis today?", and participants (unemployed \[UEmp\]) answered (Yes/No): "Are you unemployed due to your psoriasis?" Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.

Time frame:
Baseline, Week 16
Reported as:
Number · participants
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work
participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Baseline:Emp,Absent/Sick Leave:Y(n=218,234,122)505927
Baseline:Emp,Absent/Sick Leave:N(n=218,234,122)16817595
Baseline:UEmp,due to Psoriasis:Y(n=120,97,52)281610
Baseline:UEmp,due to Psoriasis:N(n=120,97,52)928142
Week 16:Emp,Absent/Sick Leave:Y(n=210,234,109)455325
Week 16:Emp,Absent/Sick Leave:N(n=210,234,109)16518184
Week 16:UEmp,due to Psoriasis:Y(n=105,80,38)21108
Week 16:UEmp,due to Psoriasis:N(n=105,80,38)847030
SecondaryPsoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status
percentage of participantsCP-690,550 5mgCP-690,550 10 mgPlacebo
Healthcare Resource use events(n=34,42,12)100.00100.00100.00
Employment(n=315,315,146)66.6774.6074.66
Work Impacted events due to Psoriasis(n=105,80,39)20.0012.5020.51
Absence/Sick leave due to Psoriasis(n=211,234,109)21.3322.6522.94
SecondaryPsoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · hours
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours
hoursCP-690,550 5mgCP-690,550 10 mgPlacebo
Baseline:Hour Scheduled to work(n=50,59,27)8.84 ± 3.028.56 ± 2.748.07 ± 1.71
Baseline:Hour Absent from work(n=49,58,27)5.86 ± 4.245.74 ± 3.015.74 ± 2.78
Week 16:Hours Scheduled to work(n=45,53,25)8.82 ± 2.208.40 ± 1.758.04 ± 1.72
Week 16:Hours Absent from work(n=45,53,25)5.93 ± 3.266.21 ± 3.155.96 ± 3.13
SecondaryPsoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage of scheduled hours
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours
percentage of scheduled hoursCP-690,550 5mgCP-690,550 10 mgPlacebo
Baseline (n=48, 58, 27)64.89 ± 34.4270.32 ± 35.3973.36 ± 34.09
Week 16 (n=45, 53, 25)68.39 ± 32.1972.88 ± 29.6973.82 ± 34.05
SecondaryPsoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work

The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means "ability to work was not affected by psoriasis", and 10 means "ability to work was completely affected by psoriasis". Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo
Baseline (n=223, 232, 124)2.50 ± 3.062.61 ± 2.992.32 ± 2.99
Week 16 (n=210, 234, 109)1.15 ± 2.180.85 ± 1.942.07 ± 3.21
SecondaryFamily Dermatology Life Quality Index (FDLQI) Score

The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

Time frame:
Baseline, Week 16, 52
Reported as:
Mean · units on a scale
Family Dermatology Life Quality Index (FDLQI) Score
units on a scaleCP-690,550 5mgCP-690,550 10 mgPlacebo, CP-690,550 5 mgPlacebo, CP-690,550 10 mg
Baseline (n=41,47,14,11)9.20 ± 6.659.57 ± 6.788.07 ± 6.266.27 ± 4.50
Week 16 (n=36,32,11,9)4.17 ± 4.482.84 ± 3.486.09 ± 4.417.33 ± 6.02
Week52 (n=13,12,4,4)3.08 ± 5.222.33 ± 2.901.75 ± 3.502.00 ± 1.41

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 5mg—18/382 (4.7%)207/382 (54.2%)
CP-690,550 10 mg—19/381 (5%)213/381 (55.9%)
Placebo, Then CP-690,550 5 mg—4/75 (5.3%)43/75 (57.3%)
Placebo, Then CP-690,550 10 mg—6/77 (7.8%)54/77 (70.1%)
Placebo—2/44 (4.5%)16/44 (36.4%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventCP-690,550 5mgCP-690,550 10 mgPlacebo, Then CP-690,550 5 mgPlacebo, Then CP-690,550 10 mgPlacebo
PalpitationsCardiac disorders0/3820/3810/750/771/44
Road traffic accidentInjury, poisoning and procedural complications0/3820/3810/750/771/44
Pneumonia cryptococcalInfections and infestations0/3820/3811/750/770/44
SepsisInfections and infestations0/3821/3811/750/770/44
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3820/3811/750/770/44
Mycosis fungoidesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3820/3811/750/770/44
Cardiac arrestCardiac disorders0/3820/3810/751/770/44
AppendicitisInfections and infestations0/3821/3810/751/770/44
Chronic tonsillitisInfections and infestations0/3820/3810/751/770/44
Tooth infectionInfections and infestations0/3820/3810/751/770/44
Most frequent other events
Showing 10 of 55
Most frequent other events
EventCP-690,550 5mgCP-690,550 10 mgPlacebo, Then CP-690,550 5 mgPlacebo, Then CP-690,550 10 mgPlacebo
NasopharyngitisInfections and infestations48/38253/38110/757/772/44
Upper respiratory tract infectionInfections and infestations29/38230/3815/759/770/44
Blood creatine phosphokinase increasedInvestigations18/38226/3814/757/770/44
HeadacheNervous system disorders22/38225/3816/754/770/44
HypercholesterolaemiaMetabolism and nutrition disorders24/38225/3813/756/771/44
PsoriasisSkin and subcutaneous tissue disorders2/3824/3812/751/773/44
Back painMusculoskeletal and connective tissue disorders16/3825/3814/755/771/44
DiarrhoeaGastrointestinal disorders22/38216/3810/751/770/44
Alanine aminotransferase increasedInvestigations6/38210/3814/753/771/44
Gamma-glutamyltransferase increasedInvestigations7/3828/3814/754/770/44

Baseline characteristics

Safety analysis set consisted of all participants who received at least 1 dose of the investigational drug (CP-690,550 or placebo).

Age, Continuous
Age, Continuous(years)CP-690,550 5mgCP-690,550 10 mgPlaceboTotal
Mean45.9 ± 12.944.3 ± 13.044.8 ± 12.645.0 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 5mgCP-690,550 10 mgPlaceboTotal
Female11412473311
Male268257123648
08

Study locations

94 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Expresscare Medical (X-Rays only)
    Los Angeles, California 90045, United States
  • MedDerm Associates
    San Diego, California 92103, United States
  • University of California San Diego
    San Diego, California 92122, United States
  • Healthcare Partners Medical Group
    Torrance, California 90503, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • Dermatologic Surgery Specialists, PC
    Macon, Georgia 31217, United States
  • Sherman Immediate Care Center (Imaging Only)
    Algonquin, Illinois 60102, United States
  • Schaumburg Dermatology
    Schaumburg, Illinois 60194, United States
  • NorthShore University HealthSystem - Division of Dermatology
    Skokie, Illinois 60077, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Hudson Dermatology
    Evansville, Indiana 47714, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Somerset Skin Centre - Dermcenter
    Troy, Michigan 48084, United States
  • University of Minnesota - Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • Saint Louis University - Department of Dermatology
    Saint Louis, Missouri 63104, United States
  • Central Dermatology, PC
    St. Louis, Missouri 63117, United States
  • Bettencourt Skin Center
    Henderson, Nevada 89074, United States
  • Dartmouth Hitchcock Medical Center - Section of Dermatology
    Lebanon, New Hampshire 03756, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • The Rockefeller University
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill Hospital
    Chapel Hill, North Carolina 27514, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27516, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Radiant Research, Inc.
    Columbus, Ohio 43212, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Dermatology Treatment & Research Center, PA
    Dallas, Texas 75230, United States
  • InSight Diagnostic Center
    Dallas, Texas 75243, United States
  • Center for Clinical Studies
    Houston, Texas 77030, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Office of Mark S. Lee, MD
    San Antonio, Texas 78229, United States
  • Progressive Clinical Research, PA
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • Kirk Barber Research
    Calgary, Alberta T2S 3B3, Canada
  • Northwest Dermatology & Laser Centre
    Calgary, Alberta T3G 0B4, Canada
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • Guildford Dermatology Specialists
    Surrey, British Columbia V3R 6A7, Canada
  • Practice office of John D. Amiss MD
    Victoria, British Columbia V8V 3M9, Canada
  • PerCuro Clinical Research Ltd
    Victoria, British Columbia V8V 3P9, Canada
  • NewLab Clinical Research Inc.
    St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • Eastern Canada Cutaneous Research Associates Ltd.
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 3A7, Canada
  • CCA Medical Research Corporation
    Ajax, Ontario L1S 7K8, Canada
  • Co-Medica Research Network Inc.
    Courtice, Ontario L1E 3C3, Canada
  • The Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • Oshawa Clinic
    Oshawa, Ontario L1H 1B9, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 1Z2, Canada
  • K.Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research Inc.
    Windsor, Ontario N8W 1E6, Canada
  • Siena Medical Research
    Montreal, Quebec H3Z 2S6, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Hospital Pablo Tobon Uribe
    Medellin, Antioquia 0000, Colombia
  • Facharzt fuer Dermatologie und Allergologie
    Berlin, 10435, Germany
  • Klinische Forschung Berlin-Buch GmbH
    Berlin, 13125, Germany
  • Dres.Kirsten Prepeneit und Volker Streit
    Buchholz, 21244, Germany
  • Klinikum der Johann Wolfgang Goethe Universitaet
    Frankfurt/Main, 60590, Germany
  • Universitaetsklinik und Poliklinik fuer Dermatologie und Venerologie
    Halle, 06120, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Gemeinschaftspraxis Dres.Michael Ockenfels und Christoph Sauter
    Hanau, 63450, Germany
  • Universitaetsklinikum, Schleswig-Holstein, Klinik fuer Dermatologie
    Luebeck, 23538, Germany
  • Hautarztpraxis Dres. Scholz, Sebastian, Schilling
    Mahlow, 15831, Germany
  • Wilhelm Fresenius Klinik
    Wiesbaden/ Bierstadt, 65191, Germany
  • Facharzt fuer Dermatologie, Venerologie, Allergologie, Naturheilverfahren, Lasermedizin
    Witten, 58453, Germany
  • Tolna Megyei Onkormanyzat Balassa Janos Korhaza, Borgyogyaszati Osztaly
    Szekszard, 7100, Hungary
  • Vas Megyei Markusovszky Korhaz, Borgyogyaszati Osztaly
    Szombathely, 9700, Hungary
  • Veszprem Megyei Csolnoky Ferenc Korhaz, Borgyogyaszat
    Veszprem, 8200, Hungary
  • Instituto Mexicano de Investigacion Clinica, S.A. de C.V
    Mexico, D.f. 06700, Mexico
  • Instituto Dermatologico de Jalisco Dr. Jose Barba Rubio
    Zapopan, Jalisco 45190, Mexico
  • Centro Medico San Lucas
    Monterrey, Nuevo Leon 64710, Mexico
  • Specjalistyczne Gabinety Lekarskie "Dermed�
    Lodz, 90-265, Poland
  • MTZ Clinical Research Sp. z o.o.
    Warszawa, 02-106, Poland
  • Klinika Dermatologii Wojskowy Instytut Medyczny
    Warszawa, 04-141, Poland
  • The Office of Dr. Alma M. Cruz, MD.
    Carolina, 00985, Puerto Rico
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • Chang Gung Memorial Hospital Kaohsiung branch
    Niao-Sung Hsiang, Kaohsiung County 833, Taiwan
  • Chang Gung Medical Foundation, Linkou Branch
    Kwei-Shan, Taoyuan 333, Taiwan
  • Taipei Medical University-Shuang Ho Hospital
    New Taipei City, 235, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • MIHC Kharkiv City Dermatovenerologic Dispensary #2
    Kharkiv, 61038, Ukraine
  • Dept of Dermatology and Venereology of National Medical University n.a. O.O. Bogomolets
    Kyiv, 01032, Ukraine
  • Lugansk Regional Dermatovenerologic Dispensary
    Lugansk, 91047, Ukraine
  • Lviv regional municipal dermatovenerologic dispensary,
    Lviv, 79013, Ukraine
  • Department of dermatology and venereology of Odessa National Medical University
    Odessa, 65006, Ukraine
09

References and documents

Publications

  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017 Jul;77(1):79-87.e1. doi: 10.1016/j.jaad.2017.01.053. Epub 2017 Apr 7. PubMed 28396102 ↗
  • Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018. PubMed 26149717 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 5 months after primary completion. A results delay was requested in Feb 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2011
First posted
Mar 7, 2011
Start
Mar 2011
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results delay requested
Feb 3, 2014
Results first posted
Sep 19, 2014
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01309737
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 7, 2011
Start date
Mar 2011
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Sep 19, 2014
Last update
Sep 19, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion